var title_f31_28_32192="Stool sample 1";
var content_f31_28_32192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32192=[""].join("\n");
var outline_f31_28_32192=null;
var title_f31_28_32193="Solitary pulmonary nodule CT";
var content_f31_28_32193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central calcification in pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign pattern of calcification in a solitary pulmonary nodule. There is central, target-like calcification in this right lower lobe granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32193=[""].join("\n");
var outline_f31_28_32193=null;
var title_f31_28_32194="Herpes simplex virus hand";
var content_f31_28_32194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex virus infection of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close-up view of vesicles on an erythematous base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32194=[""].join("\n");
var outline_f31_28_32194=null;
var title_f31_28_32195="Patient information: Stomach cancer (The Basics)";
var content_f31_28_32195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83156\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/46/1763\">",
"         Patient information: Gastritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/31/19954\">",
"         Patient information: H. pylori infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/58/14242\">",
"         Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/24/5506\">",
"         Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Stomach cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/stomach-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12871995\">",
"      <span class=\"h1\">",
"       What is stomach cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Stomach cancer happens when normal cells in the stomach change into abnormal cells and grow out of control. The stomach is part of the digestive system (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). There are different kinds of stomach cancer, depending on the type of cells and part of the stomach involved.",
"     </p>",
"     <p>",
"      Some people who get stomach cancer have a condition called H. pylori infection. H. pylori",
"      <em>",
"      </em>",
"      is a type of bacteria that can infect the stomach and intestines. It sometimes causes symptoms such as belly pain, bloating, nausea, or vomiting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872010\">",
"      <span class=\"h1\">",
"       What are the symptoms of stomach cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, stomach cancer might not cause any symptoms. When stomach cancer causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Belly pain, especially in the upper belly",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        Having no appetite, or feeling full after eating a small amount of food",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"       <li>",
"        Feeling tired or short of breath (from a condition called &ldquo;anemia,&rdquo; which is when people have too few red blood cells)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not stomach cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872025\">",
"      <span class=\"h1\">",
"       Is there a test for stomach cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Tests for stomach cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Upper endoscopy &ndash; This is the test most often done for stomach cancer. During this test, the doctor puts a thin tube with a camera and light on the end into the mouth and down into the stomach. This lets the doctor look at the stomach lining (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"mobipreview.htm?36/39/37490\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Biopsy &ndash; Doctors do this test during an upper endoscopy. During a biopsy, the doctor takes a small sample of tissue from an abnormal-looking area of the stomach. Then another doctor looks at the tissue under a microscope.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Imaging tests of the stomach, such as a CT scan or ultrasound &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also check for H. pylori infection. Doctors can do this in different ways, including breath tests, blood tests, and other lab tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872080\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the type and stage of your stomach cancer and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872098\">",
"      <span class=\"h1\">",
"       How is stomach cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Stomach cancer is usually treated with 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to remove the cancer &ndash; During surgery, the doctor might remove part or all of your stomach. If the doctor removes all of your stomach, he or she will reconnect your digestive tract so that you can eat.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Sometimes, people get chemotherapy before they have surgery.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Stomach cancer can sometimes be cured with treatment. This is most likely when the cancer is found at an early stage. But, often, stomach cancer is not found at an early stage. If your stomach cancer cannot be cured, your doctor can do other treatments to help with your symptoms.",
"     </p>",
"     <p>",
"      If you have H. pylori infection, your doctor will treat it with medicines. This usually involves taking 3 or more medicines for 1 to 2 weeks. Treating the H. pylori infection will make the infection go away, but it will not make the stomach cancer go away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872113\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests might include exams, blood tests, upper endoscopy, or imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your stomach cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872128\">",
"      <span class=\"h1\">",
"       What happens if my stomach cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your stomach cancer comes back or spreads, you might have more chemotherapy or radiation therapy. You might also have other treatments to help with your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872143\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for stomach cancer involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12872158\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=see_link\">",
"       Patient information: H. pylori infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=see_link\">",
"       Patient information: Gastritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/24/5506?source=see_link\">",
"       Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=see_link\">",
"       Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/28/32195?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83156 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32195=[""].join("\n");
var outline_f31_28_32195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12871995\">",
"      What is stomach cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872010\">",
"      What are the symptoms of stomach cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872025\">",
"      Is there a test for stomach cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872080\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872098\">",
"      How is stomach cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872113\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872128\">",
"      What happens if my stomach cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872143\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12872158\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_28_32196="Foreleg and foot muscles";
var content_f31_28_32196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Muscles of the anterior leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32196=[""].join("\n");
var outline_f31_28_32196=null;
var title_f31_28_32197="Thyroid extract (desiccated thyroid): Patient drug information";
var content_f31_28_32197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Thyroid extract (desiccated thyroid): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/39/9846?source=see_link\">",
"     see \"Thyroid extract (desiccated thyroid): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/57/22422?source=see_link\">",
"     see \"Thyroid extract (desiccated thyroid): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Armour&reg; Thyroid;",
"     </li>",
"     <li>",
"      Nature-Throid&trade;;",
"     </li>",
"     <li>",
"      Westhroid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat obesity or for weight loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add thyroid hormone to the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thyroid drugs or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to beef or pork products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3508599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Overactive thyroid gland or weak adrenal gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron products, antacids that have aluminum and magnesium, calcium carbonate, simethicone, sucralfate, Kayexalate&reg;, colestipol, or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling more or less hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A change in weight without trying.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bothered by heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Grouchy or touchy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach before breakfast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11091 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32197=[""].join("\n");
var outline_f31_28_32197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012450\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012452\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012451\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012456\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012457\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012459\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012454\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012455\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012460\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012461\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/39/9846?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/57/22422?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_28_32198="Bullous reaction to arthropod bite";
var content_f31_28_32198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52794%7EDERM%2F60230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52794%7EDERM%2F60230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous arthropod bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules consistent with arthropod bites are present on the foot. An intact, fluid-filled bulla is present at the site of one lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous arthropod (insect) bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy1veomAqdxUTioZZWkXrxVWROKvSDioHXioZRSkjzmqc0IJNaTpnr+lRFOP600xWMSa3IGeKqSJtPNb0sIx0qjNBwTjrWikJozTmnxgE471M8RHAFPjiHPFU5Ejo1xjgCrsQGagiTj2q3EvI4qGUWrVS8iL6mvQNIjKxIOOK4rSIy90vGcGvQtNj2quR1rCbOzDR1uXoFzLjOABVhOrEduKWOLE2VHapjHtJIxk1kz0UyvcsRHkjAPb1qaFiVCBeo6UsiecETgEc80oUrOdo5BFK9y1sWbWHAZWBBznipVjx97OM5qyiZ4CjcRziraRoFy/GevNNR1J5itZsfOOecDkGrK4k3Z5Y9PamwRFA78EelQwhhM5AYZGQO4q12JbuXbUnkMvOeKtQr506pt+VR1quoZUyMDA6eprSslxErHIOOauKvoQ2EnlxhUCnGePSmxsqhhsAOOM96bdpISrDpnAoRsI27nHTNVIlE+5goYHGBkjFQSSMZ/uMQOnpzT4SfLwxzx2p0gEcYYhs47dqkZHM65+6CvaooHV7skjHH4ZqxHHuXjBDAnNRzW5ZwBxIMHPY1aQXsWthaRWB+XHQVdiAwuEyc+tQwkBdr8+o9asgp2JU9fwqiG+gy5BKhs5OOcHBpI2KrlQRxz6mnkqw5LMwODjHSrASOSErGrA9iTTEVBOXBG3aoHrzikGDwE4Xgsoqs8MqyJmPlSQPetK3XEK9mxyDQncbsiiYGL5JHrk9fpU6DamBxjqM052USA/w55OOTQ2CWI6H1oFqZt7EJZUUBw2cnb6CnhGWEqFwB3Iqy5PJVcHsagaU7cNGEx1Izk/WpGMkz0J568CoTFtYbwdx680skpBUhhzn600Tg8ZGM0rj1IpCgOcjHfJ5qOI5XKcKe55rPuLhzdYZDhuF461oRgBRjp/KlfUGrErKyISTUDshGXxv9PWmXTlUOMknpiqUczFmVx8x6k9qGxJC3TsTx06AEU2LzOrYHFDK4fdjPHepIW3MRwDUjZHtCtySWNQXDCGUF2AJGB6n2q3cIq4cH5s1m3G2SbPGR/FUu6BakbnzFbbmqjoxlAXk96vThFA+bOeMVWDbWACc54pPuVsSeYIUGThcfrUXmYQtkEmkuYmk5ByO3vVSaVI8KTn19qLk2vsOjDkHAG08cilchVIBJPenl1wuCSBzULDe6tjpyaQxlurRg5GO34UqfK5YDDHjNOKDqScHmoZ5cjC5wD27UCepLJLjgfj71TuBIzfJlR7inKJMEkHHp3prk5YE4GOCTU3FYjRcEggfWoZCxbaT8tWAyn8ajl+bj0oJbK0xI4I69BRVa5YtKFBye+KKCTAYd6iapj3qMiu1o84gcVCwqw3U1EwrNopEBHWmMvtU23ml285oQyq8fHSq0kfpWiV4qGROaokypIfamiIA9MVekXkVHjmgRHGnT0FTouD60gAwakTk0CN7w1bl5NxHQ12lqDvQdK5/w3GqwBjwTXU2abpFc9BXNN6npYeNompGwVuRyBSA/M24/L7U/ygzM2ah85UlILcdDUtnVBEkRGHO4cDip7cI6ZY84qsFIZSi/Ke9W9hdgFwexI7Uo6lvQ0LZmKkMQMDgUtsRO5Bydv86aB+7ye3FLYMFeQHvyKvqZ9CeUui7ioXtg1KsSqiyBuT6d6i1FHaEOnY5IogcFUY/wDNF9bC3V0PMYkdQTg56VoxDlkx8ig4rKS4JkOQOTwcVoQtI4AwMHkkVUWDRYUtJCN3OO9NKAAmEbieuTjFKUwSwOBjNOTryoGepHNXuILVFjLDJOSKluFAYvhsg9OxqEyLDKq89fzqVtzMpwMEE8GmhMfFtx93GP1pyBcBuuO2Kr3DMpRVUgdc1YtQ5Cq57YyPzxVITROm0EfL93vUkhwrbEJPTGOPzprxMgBUqcdcnrTo5AwOwnaO2KokhjURj5u/JyKvWrgg7m+YdjVcx7huOQc8DOKN5GQOcDHSktA3Lc+1lJBGduRg5JquoKpknAPv0qHzzkqJF2+g/lUsQOf3pPHX6U27itYqXLH7RHhcE/Xp61KH2MCGz+HFPmYbySpJPQ5qEOSGAAGOh60hoHkyWGSp9RVfJVTlSz45J70x5ylztG0jGeKsB1bHoKQ7GWYn81m+UgnHXpSLGVJBHyjmrJYeY5XPHNRSOSBlSQOpzUFlERkTF+QCpGDzgU+Nx5uFPA4qYjcMkKOOoNQmMLywPHO7oTSQmOZAyHJznoKqvhAOgb09ankLHIAAGMmqN2wDDByepNNsSEuJiE3fMPaq9pKxl8xckDOaYRLK7bm4xVyGLy7cgLsJHI9fepuN2I7qUsxKZzjNVY2IBLqefbpVkjkDPAqMOfMOcHPfrQDdiCZVZjgHI9D3qDzNgAK5OMVc3IjMFGWGefSqQjzIWDZ9BipYIkTLjJGD29qqtbhySyk44GKtudvT0zTYi+0hsYHeixN7FKXYrCPIB9aWMDJU9B3FOuShJbABpm4EDHUds0kF7jXI8wqCRxwKiKb5d2QBVkLgnkEEc+1NkUKDjsKBXGSOqhguM+9UJF4P8AdJ70TOd/zNhugXHWmLu3KPTOc1I9hI9xchlOAMA5psxKsFBzmpmIUEg1QW5SSUr3HNMhirxkEjB9qKZJKT93GcUUCOfPNRkVISD0prDiu5nmkLD1qNhzUzUzHNRYZFijHtUhoC0rARsOKhdeKtFcjJqNxjpTsBQkFQHrVuQVWYc0CEWpoRmRRjrUVXNPj8y4RcUnohrVnY6LBiJBngAV0tmpjI+XvWPpkeI1VeCD1rdhYAgsfu9K5W7nrU1ZItKxIw3BY9TUDxLucEdOc0XDEum3oDU7L8hfaeRyKz3N46Eum/Mhx/DV63OzGwjBOefWq2lqvkk927VdihUMCeecn2q1dLQTJ5ygQArz1OaW2CKwdsAY4qWdFlEeB8p4yKp3sbxQ7YmyW6Yq2+pK7FovgAn8uxq2qIsY8vaufvVn2iDYA+c4zzVrKhgQRjvRcVgkhQHc3PPSr2nqrRngDPeqsiOYwF5Q9T7Vb08KEKNgMD+dXG1wexBc+YlwqjPPUDsKuKoyMNz16UrQpvO3OeuSeabxlUcgDtinsS2Oli/d+ZgkrzxToX3xA8DIzg1M4CwAqMke9RwKxLM2B6Z9KpKwr3J9pLKMgY603b5fA788VXSQljuPIPWrMYfAbsOOlUIfM8aRHzCQGGVYcjPoaW2cqGKsQWGO1Qkl0xjcB2P86s26jAXA9uOlCdxEckuAisoI67vSnO/zY2sARwaimUq/CDcT9/09sVM6qEGX5HHXigGVxbgzBgMuSc8frV3coTa45Awf8KEIULtG4dziop2+fdgcDpmnsG4yQBm4GABxVd1c/KXwB1ApHm5OCF9QaJ5WZAUXPbNIBkcA3F3UszHOT19KmeFVXOOB6VFbPyA2c0ly+FbBJ3ZGPSp6D1IpuWOSOnGO1VSTyQSR3NPV9wO4nceKZsYM3zYI5HtUlIVThScDArPvLoDOwB+MGryAeWQ2ffHrVSSIDJGQc9QKTvYNLlW1nEoyDkcnntVe4Pmggcr79qmhiEQYD7pHQdqPKCAE8nsCf1qdx6LYjhj6b+Gx0qwULLnJUAdDUKFWcc4z+tJeztFGdvPHemn3E9SKQmJW3EsDyMU0qRGWGevQdKIAZYw0nBz3pl67RoEQml6CfYjLZkIByAOlReYobaMhj27AVDYozEkjGSeTVuSJeHABz1pMNjP3v5xLcAkjFWbiXEYRRjAzupGPlyA8Eg8j2qKZgQSepHalqFkzLPmyTSMVzH0z6VZVipBAyO+KbKm2MkDDdOKfZ5FuWY5Y8VKRT2HzSnrjaTSZJjJLfSonO4MNuQPzNNupgsB2AjHQZ61XQzZSubhFYKzfMfbNNaVghP3R61C4WQqwRi+euf0qVoyABgFj69Kkp2RGsmYixB+uaiAjCl2C+xA60t44jKoB8zfkKiZgw2ZyaV9SGJGC7ArwKKYrbSMYHPNFUZMySKafSnGk4716B55Gw5ptSHpTTSsMYRmjHtTsexoxntSsFxCMiopBVgLUUgp2EUpBVV+tXJRgVUes2Mj71t+HIvMuskcLWMBXT+FoSEZyOtRJ6GlJXkjqbb5SBWtbx7xhh71QsIwWywJzWjC2GC5Ga5z1kWNgUAEDPYU5ZA8mxec9aifMj7weQcYp+noftDseKXWxorI0rRArnZgYobd9tYjnI706H5TIeobtREpa6EgU7fu9aJPoT5lmI7InXkMTxnoKtoiSRoN35VnXitFku3XrV2wLGIhgAG53CqTtoxSWhYWBFRiOQBUCqPtCxlQR1HpUiMzRFAR1/GnxqI5Nm04x96rsSTyqPKACmobeMBQ3PBq6wKqCFPTiqnmhZVVhg/ypvRgi2sokRScBsc1Vmdt4IXKE49xTrh+jKAv4UNiRUUnjuBTGW4pDtUgcgdKnC7kBB3fhVVW2BVGAMcn0FSxTJtAVvmPGAOKtGZJFDGHbIYJg5xzViVUMYO0jAB571DEBjJyexzT5HJgJQneM8UxC27mMEYHy9TUoOYT5ali/fPQVnKSXYk9e2f6VZBwpAYE9fTFBXKKHBh3BcbTgk8A1BI+/Y0eSCeB6VHcMyg4B2v2U9D6mpISyrtlH7z05BFAdC2JCnDEdM8UkjKY+f4hyfWqcquXUAhOasSsFhxkcDoDjNAikIz5m8Yx6VaV9qruXgdqa4JywCj29aqyTMm9WbBPQn0pbBuSzy4ICjr1PpULpvOWOc+h4FQo43AAfOKmlPmKAMY9+KTasFrDEjMUjK+M+3IqOUhSWIzx+dSSbo8AAY/iqrMcoxTkkcCpARCXzt6nrSMw25Xt1xSNtSMYOGxzjtVPzikjDnjpSbK5SR87s8YbvWXcXKpKBnk1pO2Ytx4IJrJmi35JjBORx3x6ipZSXcsROHYFchjSzRllbJzjoagVtmMgjb26ZqxFKXjO3HrzQhSVhOFTdn5j27VHsDRknknrTy4UhWwGoSRR06emKCLlOAlFKMQSpP4ClztQ7OueQTSSICxO3H9aqyzEhsDjvUlWuPdvlPGW71UOAfl5OeamWQsD09TVeRHMitEOp5FDYkTuqquTyeuKhEig8Dg0+4DEYBA+tVmG2MA447ilcLDLp1R1GStRsdxOBketNl+Z+SPxpkMg5AGaL3BkMe9ZWOMADjPeo1uPMdh02mrLgsjY4PqarzjAyFwTwT60miW76sjuB5rhlGQvc1TBA5bgjuKukfLtFULlgCdo9uanl1JuQGTfJhckD9aKar4PQAjvRWiZDK9J3p1Jiu884aaMClpKQCEUooooAKikqWopPagCnKOetVHHXFXJR1qq461m9xjFXcQK7rRIPKtkHtXHWMXm3CAc85rvLNdiKCKymzrwsbu5qW7AbQOtWY12z7vUc1VthumXHQcmtUMseGYferDc9BDYxufYODmrqMqY4GT1qGIKrliMMeBUpjLIxbHHFC0GTQPv3KpPrVi3TAQknJ7VnQgxuNnHtWhb3Y89F2dehprV6jehZeET/AHydq/w/1qR2EYRFOV9qigA858tyT61YaMtFIcckYUmmtSdiuH2EBec/ePpWlZYZTIDnHSq6wqqhcAYGMU+wcRxuoGOcGri7PUT1RdWTe338jPQ1HNCAwYKOTgnNVS+2UkkYP3atly8XTkn5fen8QrNMqXSkrsJIweB60+zO2cgkYxg1LOm374OW7elFtbiQ8dQOtND6Fzy8j5QNp6561FbxDzmaMYPQCrCAqAM8KAATSSjyCDg8nqOlWZlhYnEZOM/WneWo2Pu4IpLe6WSIADDdOaguZfL+ZTwvY1egrO490Qyh2PUdB1xSlOdv3oyMh16fWobZjNGS+MgdvWozdhYPlDGEZzz0P+FS2irMtsqlMbAfccH8fWmYMrHccuOnPUCooJAy7jlcc80Odrljxn1pBsP8yMY3fNzzn+Gq91MmCu4EN2Apsk25juOB39KpTjMuVHsCO1KTGoky3LEEK2CO1MQvK373vyfQVXETMVOCvzAZz1rWSJRFyOvXHelZsbsiNFVVVs98Dio5W2qScAe3ep5FRI8K3Tt6VRViz4YZ55oIvcjDNJuIb5j2pmGwA3BqWQiPcVwvr3qpNPt5xk8AHPSp0BEshHbO4noO1RNArtnueTk1JExkQseD3NMZW2sXfI7UWKTIGG15FLE+lRl9pXd3/SnohL4ycep702fG0sMGk7jKTMslwzAcdMetTMqxpwcH0qruVH+Xgk9am2mRcuQMd/WiIpFV0lZ9wBC57VLHkDGOT1q3GNoGDz7VXupAMMvTpS5bE3uMfjH61UnwH3EEDHSn+azZC9f5U2Rc9ScHqTzSY1oQRYZDt4I9KUDkHj8KVAsSOAf/AK9V5JguWY8A4pCFlJBY1Tnl8xwFG0AdKkd85JPy9qz7loy5G8qTyMDrUt2KRJJiOEnqSaIlQDzACOKiTcQBjgVKdq4396UdRSY+Q57YNU53y+TzgYqe4lVSFXg1UlY44OSaozK5mXzGxzxVeRssdvI7mld0+6oJxUBbGVQc96ExPQilALE5xRTJCec80VRImeTxR70d6K7TzhD0pMU7tSGgBKKKBQAVHJ0qTpUclAFWWqz96tS9KrMKze4zS0GLfcbyOldrbRErnNc54egAhU85J5rsLRAIeTXPPc9LDRtG5NaRhDmrR3OqsBkL2qKMZjx1JPWrgKpHtHfrWb2OocsRkdW9BnFW549lsFA+91qtp7hpCAOlaErgKqN1YUJXVxbFaKBcq5bLj8sVJHCVUHrg59/wpbNNhJPzAA1oQBNuWx2/Cmoj5mVnIijVyvzHGP8A69XvtIMalUDADGaoXsoEhRxkA5UVZgUCDggZ5OKqN7tCa0QGQyncuRg9PWnOXxuC7eaitvlm6hl/iNWZpkG8Iu4N+lFh2E8sFWGQCTwcVdsU2tiQ4Ud6rRkYHXcPbtVkOSo2jH1rSOhLLF0vy8gbcZANVLdmQFge5wKtsA8WSeQOc1mQSGOcnkqOgIob1BK6NSE7lwSMjrmop5n4QAnc33j91QKZ57Fmym1CKfbOsw4IBz8vvVXuTaxYgi8qM4YEjuB296dIu4YIwTwdp60+FgzHOBkYNReai7grH5eMkdKqwXuJHEGGzGMcFc4qOZG+QKCVBwcYqc46/wB7gE96akoD5PLD+7/WkNFG4QlZFlAVsZ3A8k9hTVnE24BWLKOfSrckiO22RPlY8HPf2p4VY8Mi4HTgUrDuimImVRyMk5JFCRKrksc98j0qzuYAjp1wMdaa+7O1MbSeRQ0K5BKqhM/wnnpzSC5Eo/dncR04qK8lIBDDnOMgUyNTjCgrkdqSE9tSG5ufKYBi53HmnxS7z398VHdxqWAOT2PpSJG0KkoGOfU1PNZ2C2hOw4yeh5waryRCRc7S3IPTtUsbeYoyD+J5okbnHKheaGTYeuyIhQMrUUrbpARhVAqvHciSUnB4PX/Cn3Tlo8IPnPQU09AaE34G48D6VE+3YTtzVa3ZpMGQlF9Ks3JGwIvQ+lICpMkZyx2hv0NJEDtJcgKOnPWpDGSmGbtUTupTCdemalA2RXlwqpwWAxVYyNJF8o6nNSiLMbFhkHsajliAXaPlH86WpSsQmXMmOmOtS/eHXAxnmqJc5JCjHqatQthFDdTzQKSIpQGJQfKB1Pqaq3MeYwuM96tcDJ7k+tV7h8theg60iUyrv7EAA06SGPfvJ5A4xURhIcurZ9jT3mBUqAM0rD1I5JME7QBj1qGRyzYI4pVG6XJNRXDqjn1oEV5MMd285HHSlkxt5PXuKY7EHg9aRiMgZzTEyBl3KdowPU9arMTvwowKt3L8EAkVTaQojZ49jQQyOZscUVWlclSc0UyOZEp6UmaWkrtOAKD0oNIKAA9qXikxRQApqKSpMVHJSYFeTkVCF3OBU7inWEfmXS+xrNsqKvodNpUflxp64roIiRHgdxWVZpwOOAK1Y1+ZAtcrep68I8sUi1bKVUFumasTLvGAcZ9Ki2EyKFPHerQUAAnrnmkaItWMawqQR8x9asxhXjBfgjmobdgU5JGe9LcvtRVHJHGBTTtoG5YiYbWdR978qYJH+1DK4X1HekQKsIUdeuKtQAOpY8bRxn+VNajtYzb1i5b5SQvSr9juEDeZkgDNI5WYqsS5yeQKmxglWJz0oURt3VholVHUgDaTyKlkh8xSythD6dqqyW8qnPQHoDVi2UooMnU9hT1vYHZK5csmBAUg4PHPellbg/Mcg4xjpS24yOmW+vNJKmZgT8uDzVkbk0Uo8j5wcDoTUqrHOVK/nmoGVWIAwUxzSIrpGOcEelPqCRYvPnXy4QAwGcN3ptsFAAK7ST/D2+lMZV8sOxIPQ+tLK4K/um6YJHemgt0LTFjnap2+uKoyKwmKh87Rggc5P+NW3mjijBZsA4z2GajkQzZdV3qv3fUUxIrrdMjhSpOPXnmlebDArsAY9MdKRoXL5Uqflx1wRTZ8sgSM+2D0NK5ehYgcNv25ZQ3HtUs1wVDYUjA5IFUDiESbcxuT0/wqBXLhtykpjBPsfWjmFy3EaZlLMzMRwRyRipoJxLvZHOGP1NQy4RkVCAc4Pfj3qSI/IQecNwuKFqNoUMfO5Jb39RVlNobrz0waq7znBAAps83l4ye/3j2pJ2IaJbkKx6glfyzUTEYXOevWoknDl2Ukn0I61LuUrliAPSh6k7DECjLrwB3zTWBmk4OKr3VyExjhMcDHWnW05kKtjCAcCpugt1HDEUbAqCR0xVSch84zjpnNS3kmwnoTUEGDhuADS8gQRKqRjOWxwufSpGYYx0Hao3G0uVYvu9TUCgZAbJbrnND0Bq5NM20g9eO1ZxlJlCr09KmlYu/yjjOKYYmRsj72ce1K4JFkfu1OemKrZ3KccsadLnYAR25NV4o9rMckmi5NrDPK8tTux61Xmk+6QeBxird5J8h6jis2NzKvIwB1oGh6AqSz1E3zb89jT2kBGBn0x60Mdq/NggUib6kTkFePpVVgc/KR+FEshBLAnB7Yps7locx0mMiaTa3GM/zqt5gllO4cY6USkhfvAsexFQwKyMd9ICw+NuQoH86pb2BJY4XtUl5I+wKAMmqKFo87wT6ZNO5PQllJZs54qrO5ckZGBUnnF2b0AqB+meg9aoybK8zhY8Eiiq9wc8gjAoqkjNmlRS96DXWcY2gAdKKOPSgAoxRRQAGo36Gnmo2HWkwIH6VoaJFuctj2BqhJzit/RIdgTNZSdkbUY3mjegjIXgc4rQtvUjkCorRCxPcVbVQAwHp1rmaPWLsSr5G89etNAaScEfc7imx/LGoB6j86nQlSvHzdqQ0PkVhKgGCuccVo+SAynrnqarIoeX5htAH61p7tsIKc4HX1oQXIkRcg/eGc0sqStGyqMKe/tVeGXMny/XB7mrKTCYN6dzVWTG7oZp0Zjjbdxg4WpVjeOR9+Dk5Bqa142kA4PHNRX5KIoRiSeTVpWiLdluZQVAx14z61QuUZHBZhtHGO9Twzl1VAM/zNSzhCuCMnOAKW4LQZbZ+0KCMpjINT3rqIMqQH6YqGEARj5sAjFHylDGepOBTXYRFbeY28q3zEdf6VeEocHPLY7etVoiI2TkBTyafPk4bopPY00PcsSqxQSLj5eoqO3++QuAenJ61DFMyuwY+zL7VYRAV+YEjrmmtRtWK99B9oGA5GepI4BpLFZYJdszSPHt4K8kYq4xEgIx86/wAS9x70yXzYnfyiuxjyCMmq5baj30KbOZ7krjOMkDFNnYOZWB245UZxzVq1tbmaXMVv5jLycHFRXNpsmPVMnJXOam1x6J2GSzN9l2naTkMSOaSFWLAKCQeMY/CqF9LJC6CL52JwE9fapg5tkfzZmDRnICjpnqCaSdymtB9zNvYhEAi6YIyRiq8txtIAZ8nnK0u5FhDYPJzj3qC3UsH83nccZ6UuoJaaltizIoCkdDxUF2ZDhVckZ4JPSpZZTGm1XA45HpVQEu3z5X0HtSZMUSxrtXcPlOfmPXNTNIqqMnOOcdzUESkjJPPoO9JLEXUMrYI5I6ZpXsJrUJSGkULkHGBntmpLfEYADgsByOwNV2Q7yWGD2zS+btYl8An9aE7shi3bkKmWw+euOtMlxHEvPLc4ojcTMSWyemDVa6Rd3DdO1N9yUPVhIB5Z5HUCkcglQMZB9ajtlaJGfOQe2KcSMcqcEUtwY6DBJJ61FdPtlUDp1601T5e7PAz8tQXBYbQOc96Lkj4ipzkkkU15iox/FTI12glzyaz7yfyWy2TzSEy1NK7JgEdec1VEbD7zZzTkbfHlTjI5NRGTLEYyB1NAhrSHfgfdB60y4kL8Lj3zQSQ+VJC9+OtRTEkuQQPY1LYEDuN20noMcGhsgYzlc9Kj2kvkDJ6U6f5V+XJJpJPqMqkF5GAyFPehz5CBRkk0+EjPtUN5MityM8dqokilcnbxk1WZWZSW61OBmMueMdBVcuCp9qaJbK0rLEMJ171Xmnyu48CnTNuz6VSdix5HyjpVrcybGTnIOM0Ux2OOelFVYyublFFFdJzBSZpSKSgApc0lA60AKwwKhOeTUp5qJ80mA2NS0qjFdVp6YCKK5/Toy849q6mzTbjHXiueZ3YWOtzYtFAjxnB71NZjzJnUniq6EoF9SKfbkpODjhjWL3O41PJGFBGAvSonJ37gMN0NWHkBGe3rRGnnSf54pS30HEmifLYHX+daiQmSFQSeB0rLt0xKpx3rXEjKT/dqkl1E9HoZ/kNGpHBUdfWktWKzGNc4OMVanYspYKPoO9ZbvjLRtiTuB1qZS5TSOq1N12KRkbgeecU1QZZAvBDd6qWkha3VpeWPr1q3HKsSnJHJwMVcZXRLVgigjWfc+V7ZovF+Y7f4M8jvU6MsgUqMjPPtT5EVw4I+Y/zq7aaEJ3KcbB4wW646jtVVJil4sYUnd0JqxtIbAPGeQKQwnzA6jj19KlXKVupOYpGQkp71PCiPFtYcqMg0trLsVlzuY8/hTVCPIBkgnJ2njir0BDEjkWRztDHG714qZ3YEPCMgDBB5HSmKTkMVbavGV61LaoZ5lDkKpBAI6bvenEY23ZicBQik4GelaKpl4/NhkCunBHQkdayLuT7Msiz7oplPyhvutWW+tTp5kQm3oOEPXH0qnJLcfK3sdnFe6Ra4lnQylRu2McbWHfNZ974u0mQIJNOQ4fPytnd9TXDPK8rMJnY579PwojhVgVYEBRhSBwD71HtW9kS6cb3Z0b6zpovI28vysbmeVRkYPYGs25mijBljZXikJXOc4B9ayrxDD5idWK4IU8fjWWGeMnBJ3DBHrWUqtnZo1hE6F8tIfJfbGq7iGbkDHerEN4nyRoe3c/jmuYs7ySDI2qwLZO4ZNWHvEkYLEFVwQTj0oVRM05b7myZ1mcxMrKzZO4DPI6fhSglcYwzk8E/yrPM4huixbLIdufQVcjkC/MDu3H5aL3JcbEtu8gkIIIHcHjFOebPKdvWoy7JGclTngnGaiKq8gw5yBlgemaDNosPL9zAPA5561UuUMgyDhieM96lQHGVYHj8qrMXJIcZBPAouQ0TwLx23dsUkgTcC3Wmeb5Skk8Co/PMg+VRVXRNh8k3ygrhVHT3piuzHoduM/WqMjOZRgZX2q8sigEcZx07ikhSVhsz5xsx+NNfATcSP8aRgqtk1VuJcOFAyTxwOlBBI2GX5j3zVKcH2znPIzV0gLjJzxVKdsvgDGaBXGKRsO3gZ6U04XO0A+3rTJz5UQ5G70psLsRuJLH26UgZHcSsgzjBx0qu0gKgsMfWppQGO4n5u9VrvHy9z6VLQBJJwdp5xUInKKozuPqajO4HLYCHjrzQ8YkKgcAHtT9AYm/PC1TcZZg3fv6VcuCsYwBgVTcDaTk0xXIZpGxtBJqvI+wDP5VI5UHIPWqs20/NuOR0qrGcncjlkzkKKqSNhsA5PtViFJLi5ighG6WZxGoJ7k4q1dWOn23iH7BLqZEER2SXccROyUdcDuobvVJGLZh3fmJK8coeNk4KMpBH1B6UU/wATrd2esX0GoSGe7RyJZS2d57Nn3GKK1SM2zoaPxoGKOD0rUwENBpelJQMKBRSihiA1G3epKawycVL0A0NJi+Xd710dog3KKxtPi2xZrctAQFbpXNJ3Z6mHjaJeC4bnqKlC5dMVEjgluuasIgyp5rNnSTDLRbQD1xmr9pGcZ79KgiCqpPJB6irqZ2KV4BoC4+32xuQexxVmZxGjkfMOoFUgWMnPSrq4+zEsuc0wZHBKGRSejDn2rEvbWcXStG3DNx64rYGI4uhCnqKtWIXaMr7ZPWlKKnuUny6omtrYJapuAaQdzSw2hZmH4/jVgMFGABz61IGKsCrAADOO9aWRDbKYQxgopA9/Q1HNI6IBn5jxn1qWdg4ZmI4GSMVCdrA/LljyM9qLhHUbD90bgSM4yDVsMGR1A24PQ96jgjKxLlQT229v/r0jkg7QDknBPfFMY9WXJJVjgcACiQhiAw24H3j2pkMpRWjJw3RTTnHygOUfuc0kNIjiuDEWDZOTwen61XnvVtj8g8th1w2QwpZ7hQWVkymO3asbUZ4Qu4BtwP3T0NDdkaRjct6hemcORJ94gMM5/Ss8RlR8jDDDgVVgc4O9QHbmtCCE7lY4IPrWd+fUUnYWzsZrjI2k5PGK37DQTJHK0ysVAGQOuav+FrNZJYdo4ZtpycD869dsLCG1thGI0BI+bA610U6aSuzirYnkPnzV9Ma3uH3B8g4OR+VYNzHsJzyRXrHjSyX7bdLB5flwIHYk4zntXmuoqDhABjrnPFc1eKizqoz51cyJQdnygcjtVG4WRJSyOVPfFaLSGJuAPyqncEMcpkLXK5I6ooWC4Mj8sMn7x9/WtiOcOVwc5rmQHifcOO+fWtnTbyOX5Cm0g/K/f6VrSqX0Zc49TXeYncSqr2FRSOWwEHell8soQhyT+lRvL5bEcAE9a1tcwZKfMMeyPhieo9aI0kTckww/Rs+tD42hhgDHIHemFlOD5nzHmnsQyK5RpdwR8dunFR2YOBGcggnkmr0YR4ySMt27VBNjKleCM5xQRfoOI2L0AGfzqqz7WzjaDUs8g2nBZhUHJQNIpIpkErOCMk9qgYkHCDIJ5peGjyeBUaOGB25xQTaw6ViCGzxjp71V83LgH73ei6ZwvygkDvUDBQAx/XvSuKwTx+ZKVZQFHek4VAqEYHSnxkt1UZ69aYkPzlmwCPSgGQ3D7FwcVDGolO5sA1anIDIVwT3zUd08ccXQc9aCUylcIi5KnioUfJJGcCm3M3mIdq8UkfyRA8jPahCZFPud+T8oqpeyhFwMmrUzhT83HpWdcZLDHNWiGQs4Cg9qilbI4NSTEEAd/QCoHwgOfwpohsjSWWCWKWFiJkYMhA53A8V2cmmTXMp1C68F3LX8h8x0F0EhduuSh5APUiuOsp/s2qWkxZF8uZGzJ90YI6+1aXiSws7zU7y5h8XaaUlkZ/3sj7hk5xnHbpWkUYSZyfi26vZdbvjqaCO/Mp89P7rccfQDFFZepxC3vpoVuYrtUbAniJKyD1GeaK6EtDnbPQ6KKKQxP5UUpoA4oATFLRS0MQU6FN0oHWkq5YJmQNUTZUFeVjXtYwqAY5rThXOAKqwr8owKv2www46Vyvc9iKsiYQlSNvbqauWf7xip6Y6VEZNo4xk9RVu0VVUEdT1qdC7kqxFVIU8npVsMyW676jssSMVXqM0+4RpFKydBQkIkhcMQWPANWFdJYzIpOFNUrdBGjYBJAzirSHFuQqn7ucU7hYHIuMOp+XGKSFnjQ7QGYUWIDxDaCFPQGpD8u47c47UDvbQSGSbJzk5647VaRibfqQfXuakgx5K8YJqdbZdmWGOarlbWhDkUbcSGQrJ93GauNhEztX8uasMij5iQePzrPurvMioDjJ5p25VqNO42Rx5qbW+U80/zggLMPbHWkV8YVwNpPGBSAKWdFYKc96C0VDMzXB2Djr0xUodkJJx1wAeQaEgT7SB/CT81N1M+Q7JGyvz1HpUrRXZe5QvpJImG/wCUScgeo9aw7kfMBvJA561a1F3lKLuzz94noPSqEI3kjjJ61E3c1+FD4CN+W6r0NbdhLGsZVm+ZuawQwJ57dqsQyEEFscHIxUxlysxlHmPSPCmrW1rPH9oVmjVcK687fYiu7k8TQi1dovmcDqoyPrXjFpc7E3KwJ/Wrr6k+wokrfMOgPauqNVWOSdFSepN4l1Jri7ZmwCTkgHg1x10SW3HrWnezI65zuc5JJrKAaQgKMn0rjrzcmddOPKitIeuRVEggn+7V6dwpYdx61VPJzXI9zqiQOCVOc5Ht2qGMtFLhe/Iq5JhflXOcVVkGCCeM8E01uaJm3bTILcBuM8k5yaUzxsqr1XI2k8Vm25ATDdAeDU6hOnPqK7E9DGUTRLAnn5snGajwFlwMsKiJdkAxgg8ZojUZLbhkdRmqMmW/MCEFB7GoS5znk8+tCSK8mOTjripYUw3I47ZpoydkTQRK4G9do6/Wobllhi+XkZqeeTykUjGKoPMZGIK49DVOyVjLVsarF1OTtB60IAqkg8elU/OP2hlzgVOzlkYA0lsD3Ip2RiPmxznikK72yuMY4qnIpiG7OfarSN+6yetTFgyOd8NhetRKzhgNwb1pj534PO7sKduSKM470ybCXMoUEKMmqdx842kZ4qNpmabHOPWnXGV5Y9RRuTexBIwQbehzVW4mHRaWUf3jxmqxGXBzxTQMSQkn5jmoXbLYUUsmSTzxUMkvlqQvJqkZSGyMelU535p8sh3c1VmYLuJFUjJs0LHWhpkMqtp1hebyGzcx7yPYVVuvGMY4Tw5oRB65tz/jWHdXClfmrKLK0g3sFUkZb0963hEwnIm1C5F5fT3IghtxK27yoVwieyjsKKt3djZ/a1h0y/a9XcVZjAYuP7wyTx+tFXczsd1RQT6UCgYGiig0AKDS0g60opCFXFa2mR9DWXGMuAK6HT4wqjPFY1GdGGjeVzQtk5GelXxFujyDg+1Q26CrkaDuSKwPTEt4RkFjn3q1F8hy2dtKINsbEng8gVLApZB8v51Nhk+n/K25QcGrrnzCVx2qvZt5WQ3PpUsDb3fr7VaYCbTHjP3m4HvVsRB4lEgIJ64qPaJZMdhzmrYQ+WG7EdKErgECwrGF4354pkUJ85vM+4aj2gEOCOOoq6k6EbTt56VSXcluwIqRSex7U95TjII47UyXGw7+mPvVnK7m4JAJAPGO9F7MFG5qzzKkYypYt2B6VmTJ50xYjac9DVt12zgnqR0ply+0q6jjPIod3uVFWAoFC46+9RJFkkOeDzUjkyRsRjp19KrCbywBksO1GlzRIdcRGIjaxwRx7VnXYnjbJBKcZ/8Ar1fmmVoiuTv64xms8P5kZkK5OeR16VL3LiY1/ujJZTg9T6VSEwHzYHNaGpoCp5YYGdprLO2PkHrzxWM9GaPVEplLzFs/MR2qeAgd8bf1qqpVsMOKejEuSoyB2rNkNGlA42jB565NOe5YqAPlI4B9frVMSfIflwf1qNpGII6rQ5WEoksrMSD1psLND8yt8x4qGRyH5NJy3Kn86xctbl2Irn53J/GoDnbwOasyAsefzqtI205UYHSsnuaRegwsQecj2NV7nDYx1q1OQ6hgOB3qtOM8cHiqLTJbSXe5Xp6/WrvllNwIIOM5P9KoW0iJIYiu5xyTmr4cqmSc47E5rsgroym9R8T4QFjz3NQI7O7Oc4A4460v2j5mypGV4A7VE8sUCBdxJPOSapmdy7A3zKR1xmrM0jBQRkY6fWqFnIXwy8g+lW5l3HAzgc5PSnExmLI7GIZxu7imO24qBwwHNPTbjBII/lTJQqHIPNUkQU7lRuDZ59qVCP4jk0xhknceSailZxNgDgUhNXJcHzMnbtFOd1CEkALUSnCHd69KjmYPH1wKCWBwxD5AxVWYNszu4oluBGAuOvFRPKBEdwPNNEshHyk5b8KgmuDI2McDikkkBRiTzVMAqCSck00IkkPdiPaqrEgkmns/Y8mq8rgAcmqSIbGyK3UnAqs8hDZpZZT0PfpVWQkrTSM5MHfnLVQv7g+WccCpLhjjjkVj3k5c7R0rWMbmE5WHWMcVzqdnb3D+XDNMiSPnGFLAE1309g2iyahdW/h+3+3Xd+LDTrKWLzAYk++4B67uMt715zZWz3t9b2sRHmXEixKW6Ascc+1d+9hpa/ZZ47nV5hYagbGe4e4IdkC/N5a/wjP6Vq9DHcpX+kW2n+JNTWzUCBZisag5CjjKg+xzRWhq9h/ZWp3Nhv8AMEL7Q+Mbh1B+vNFYNu5okPooFFdBmKKXHFIKUUhAKdSUo5H40MGWrGMNLnHSugtUP9aytKi5ya3oVwcAVy1Hdno4WNo3LtqCee1XRjbgdO9Vbb5RjHHerWzAwvNZM6yxHiSMDdnHFTyyeXtXgY5qqpWLap4arKrvRSw57fSmBXS43XDdwf0rVt38tA2M59Koi0DZIAHOasRtsYBhjPAoSsN2exaSXyiQ2ME5q7BLkbSc8cVn3UHpyeoxUtvuKADj1NWnYTSLD4RcHbuP6VTVWabnlezCrJwyvx145qaGErGGJGR0o3C9iXY7RYYcY79qWKIITsBwOSPWiK62oVYZbPepw3mA5GDjtVW1JRDPh3Xbj3NRuqMWU5LfoKgu8qoO3nIOM1dttzRu7AbiKNyttSoyGIdeDx7VWeICQGXO0f3f51ZeQNIYjg4680zcqr0JYg856UrFxZWaEMj5OCf5VmTM8LBUZSOpPbFXMOJNqklW5xVS49cEZ5Ix0qTSLsUNQltym2QMeDyp5NZMAjaPByd3Kk1p36L5eSMDqDisaCXbKQuNuc81lPc1tdXFDbCykZFPVygymOetEnlliHBHfPvURmGAOQcVg0CjcsqWwSzY+lPdicEYFUUkOQeqn3qZZVJ56+lZeo7EokClsgNx+VNMg7GonkV2GzAFAdVByM5qG3cdizAvnZHaoL1Ah61HDMytwcDPFOupC/B69TirTTiTZplPeRxnj0qGRmY4GKeyncT29KYCWZRgc9CO1EFzM1bS2LVrDtbduzuq9cIAgVR0x+NRWaOpG4fN71YkkbGWAz0yK7YqyOecrsrnEjAjqpwaimhErMxHAHSrUgVuijJ56U1VZyDtAwM0mtSLi2zLGgWIjpn3q2rHyzuOCexqiRsAwPmPcVKjbEJb9aqOhlImBXdxgAVVldi+T93PFRrMS+WGBnjFKWJkBGPm9adyQdiFPHT1qvG7O7Enj0qz3PP1qlKWEuYxxSa6iuLeOoPDY4qFWPl8nOelLNGS3Ygjk1CXC8E+wp8upN9BGIzliC38qbIy4x37VHk+Yc/dpjSBmYjoOlMhlRm2sQ44z3qKRifpTrgM2cfnTACoAbrTRLZVkzv9hUFw3PFWJmC59aqFgetUjNsgkcgjNV5WO3I61NM25unFVJ3CqdvGKpGTZQvJWThT161lucmp7lzubnNVSc10RVkc8ndktoJjdwfZiRceYvlEHGGzwc9ucV7npthrKWmy98LWEl+832p2+0gK02Mb9gPJ9uleQeFIU/ta2u54/MgglVyh/jwckV6dc2lhdau+qJ4ltUgabzsuWE6DOdu31HQdqib6DijK8QWOqQXbXerxMJLlyxlBDKzdxkHHHpRWhrGpWdzpepNBLltQvxPHbd4VUEbm7At6UVkUZIpe9FK1dJkJThSAZpaQCinIMsB3poqzZpvlHtSb0Bas19PjCxjPWteEZ5qlAgAx04rRgTaVHauWWrPXpRtEtWwweeat+ZskAIxmokUYWpn2tIMdqg0CWLzHBOcVatpAkixE8GmRg4PXA9KWRV8xG6MKYF8sqKVOBmnLtm6KMLUE4/cq3U+tLaOVy3pTBF3LfKFAx706UMkeQtQW0zNIckc1oNnyx6etNaoL2KMDrI5DcYq/HuHHYdKgjgCyEsQTjrTpJFRl459jVbATNHHsy2Tg/jToi28BTyfWk4ZDg4I4plv5iSbWI4OBzmjZiLEkBLnHzZ5NGGAIAwMdKVmdTkHGP1qvJLlGYknJ7UDIpY8OuEwe5FNm2tHgcMSRVkOzKAY2zjrULMQWKpwo6GhIaZnhF2dWcg1SugXuGUsQFwEI4B9RWq+55D8oC9wKr3qKzDgbRU2NUzNupPMjwBwnBxXP6hHGWVkOQnJ4wTXUXMedgDBc57VkzWUaSc5OeRnoaiSvoaxaW5gyHL45OOgPWmiIMwLHknBHtU93bsJyUBDZ7VXeQhBu4B9q55KxrvsJcKsTnY+YgOoFQpMEcMBn8OtTAKUzuDewNRiP5d2Np7etZSGn3AHqdpwT2pDKQeTgUjt0AHPrUQyTgjpWckNFh2Aj3A/N/dFQNI4G/afzp4O1c9celNiV7o5GQOg4604wctEK5FFK8hIbOD3x0q1CWiUMV69M1PHbiJgjqCe5PekuB8jIB846ZNdMKfKrkSkmT25bBZzk+1CSE8EE4OBUULGJBvHPoKm37mUqo57+laXMXuOHzDHzKo71AWZQRjCg4PNWB82QOQOvoarl8hwAWycHHaqRI6SYjhR04pj3DsApwSemKUR7I8vnPvTBEH7fl2qW2S7WEtwzElhgrU8bALu7jpxUe4ABBjJ6k9qVlIHQ4q0ZSIhMS5A6d6r3TEAc1KGXIyOar3BU9TwOmKBaIGchDk5GKqxDfuYj86sjiNS2DxzVd2CgnPWmQxhPOM1CygOOMKKGbjJNVppDx6UyQuH+bKnAHaqjXDOx4GKfNKB0HNV2fAPFOxEmMkfceRUE0oUAAfhT5WAHvVVnGCSMmqSM3IiuJCuCPyrIvLhiCB1J5q1fTEDC1jyyljg1tCJzzkRuSScmlhjaWRUTkscUw1u+HLPcxnYdPu5q27IzWp0Ph6zgjuLGCbAgeVFkJ9CwzXolxqdzAmo7NHszJY3yRG3FqMtA2QO2ew+b3rgrS3+1XkFuGCGaRYwx6DJxmumkvdK0vVrgR6hr/wBrizbvOjqCwXjHPbjjNYFmN4siaDxNqcbsHbzTyFA7DjA4GBx+FFUb54Zb2eS2aZ4WYsjTHLn3Y+tFAy1QeaSlFdBkAp2Kb3pelIB31rR0pDuzxWcoyRXQabDtC1nN2RrQjeRoJHhAau2yFiCe1QbQVXOatwsd42jHFc56kdic9CR2p9kMktnNKFGOeCanhjESHHU0rFXHxTFZNv8ADVnggk43H1qGOMl8Bfp71ZniymT970pgPVd8YXnHrUkaqkjR7QQRVS2Ei7hkn29KuKw4HU9fenuAoTyzlcYq4pIQN1FQlc5+nAp0LYBEueOgpoCYNuBA4HrVVotzAhsnP50twNrAqSAetTxMg25X8ae4tgEvlMFwSSMn2p43PJiM4buaTapdmOfmqxDCqgnjihJjuAc7AsgAYdxSKFBxjJPWlnAZfmGGz+lUJZHSYKAW/vewp7CNQRs+E6DpxTH2xBupI6g96dbysoU5HHXNJMvnktkKPWqfkSr3M3czu3YjtjrVKfAYl8sP61qSx7MHgN3JqtMsUaoDgkdR6ioaNk7GbCu/qeT0BFVbqF5GDDAKHt2FbJijC71fnP3SKq/ZkjYk569+9Q00XzFAW6zc8Er/ABYqldWkRwcD5eDir0vm7WEa7QW6e1UZz5JZT1PNQ2Wm9zNuNPjblF//AF1TuLWaJQVIPfArbZlkAwcMT9DUcygiMcYByamSTNFJnPtDMU3MMJ60qW003IOB+VbdyA6N5YAOOQRTY16A4X2qfZRH7XQoQ2yBgr9AMkH1qaZhEqrGMDHX+lTyROsgGM46e9RkCThk+71BqnGy0M27lQsHUvIfwp5zwcAqPWnB1kbAReOM1dhRWzu2g+lHKxNlXYrqGTg00xmIcEY9DVi4jEY35wO+aotKZSARx35oehN7gtwWyu05J6VajhHOBtNQWkZQfMeRz71aj5Dk0LUiT7FeXc7Y607O1dgFSK6hG2j5R61VZ2ZxkjBqkupm3oAVRKCefWh5AQ+cn6UpjUruY4qEuqg44HbNC0IK123ljcCRn1qEcxhjyfSpXO+Ql8FQelQXDhThQMZpiYSsVUY7+naomwwOTwKY0hANQvLuyDwD2pksZMyhcZqs7fLyabcEbuOMdBUDu+7GOKZLEkYbhnioZJSzHA4odsvk1C7YPFUZSYk7cDPWqVzKIxzxUssowSayL2Vj7itIq7MpMrXMxZu9VDyaczZNMFbo53qTWcDXNwka9zz9K7a2hWCFUUYAFZXh+y8uIzOMM3NbJHHHWspyuyoomsVje/tUnDmFpVVwmdxGRnGO9dtrE2trqdwq+G7SWNWxG5szIWT+Els8nGOvNcrpFtp8yu99qjWMqMNmIi5bvnI6Vsf6B/0OF7j/AK5Sf41BRzmpmU6hcG6gW2mL/PCibFjPoF7fSim6jt/tC48u5a7j3/LcOCDJ7nPNFFwLFLSYpc1uZCMN2MkjHPFKKXPFA5oYEsClpVArqbOLbGD6dawdKi3ShsZFdPAvy47VhM7MNHqSR4KAZqVBiQY9KI0XjA4qfaN68GsjuNDZ/o6N/F6U4KXK57dRUYbKKq5qxaKQRu6Z5zQCLUIMYB65/lUjFWcFulRXDMRgA4BwMVdhi2wq2OarcNhkaBNzY5IprRkOrLjippG2nkdaaFyh2tzQPcerkFiRlqRADzu61UV3+0cg46E9jVllBj5P5UwJZI1K5Bziho/kAwd3UelQgkbSpwtXIZCRwB9KEAlvkowGSR0zVczPHMQec9farcQY5ypAGc0yS3V/mAPsaYEkeGj3hgzA8CnrCgcsBnPJ4qqqiBhtyGzkD1qaKYvNtdgAOtJO4rdhsm4N8uAPWplVWiAGc55p02DwgyhHeq6ybZSiY5/SmHQdcqxjOcgVkB/34wA+RxW24wG3Hg/jWXImWJGBg9CKTZUGRTynaSc9ehqJGfLFhvJ45FWii+VuA+8eh5xVN5tkg+UAnrSuWhxVRJgAjjkVn3KK7nKIAeOByPerbtk4Kkn+JhT44v3hVo8AjqaT1GmZE0MaoAh47Y61RmZUZQxJI9BWxJZLHISpznPU9KpNbBeWHzZ6Vk07miempCsWRuDZNNuFDEAg4FWjGkZXJ2gjPWq9whZVCNnvVpCuN+RVxgnFVplyCVB5OMVbTaI1JyX7ioJkO/KHP1oZJTSHezAHayYyKmk+VFYEAg0JDtZyTl2POe1Ew2xbTyOuahtgVbucynCkkjtjiiNCVL4AA71LCNzgY+VRwacWGSOD7Cha6sG7aFcO5I4+Y8k1bQlV5X3NVmQLIhLEdzVgtmNtvQ00ZNlRndmy3TPSkVNz73B56c1I2QOF5FV5j5agnOc01fqS2Olcj5f4R69aj/1qZx8opjEsueeaSMFQfm4oIuNmJBGAKrSJ/E3SnO2WPt0qK5lGNpPPpTJuVblzkVUd8njrT5WO/AqKRlHPemS2QySH7pA9c1E0mBwRTixbPpVWQ8kHOKZDYE4BNQSOOaHJ7VXkcYJPFVEybIZnwCewFZE8m8k5qzeT8lR0rOY810RWlznmxCcnNXdItDdXQBHyKcmqQUswCjJJwK6/RbQWtsCR8x5NOTsiUjQRQigDpSmj8KDWG5oX9L0a/wBUSR7GFZVQhWJkVcH8TVz/AIRLW8H/AERf+/yf41k2Nv8Aa7+2tt2zzZFjz6ZOM11ktp4XhguJnsr8w294LOVzcc85+fH4HiiwHIXttLZ3UttcJtniba6gg4P4cUVZ8QWy2WuXtskQhSOQqiBiwC8Y5PXI5/GikAvTrS5pD0pO+O3augyHUZ/XijoKWAb5QKlsDe0dNqDIrZjIHfiqFjGFjUGtKNAcDt1rmk9T06MbRLUfCLVtIweaqrl3CjoK0ApW3HtSNwtUIckn6CtJUJUAEVlwSYccc1qCUKQOxpqwNMtYCoueauIdkahhx2qv5IaNW7VIsymIo33qtaEbi3QBABweOCKrNGUQ7c4Ix71Ix6Z6dqnP3FPGKVrl7EFvCNgC9RzzUwBVDuxuPamwEA8HA/nUs9p5m0qefamkFyMxl4snkdhSWSsAQeuatKhRMN0HSgHaM5BB6/ShoaYySXY+zo3Q+lWHXbCMsD6VXba3KjkUSbygyPbFAhkxEjAYyQPWmxoFkyVJPfNJHGzIXGTinQM3mbmHHQigZf8ALDR9MHtVcwbC3y/MeuasKQ4AVsfWmyqzBvUDg54qmiUyptbqDUFwjMPl4Pc1ODtznnB6CiaRGTcSAMdKixSdjPZWicByQcc5qK5hTywQwD9RV3CTRZOWPbPWq0yoCB1buDUsqJBbxZQO30PNPaUlgjfepsUpO5NowOdtNaMs/mDIU9aBsbcHNu5BwwrMRGMuTyp4zWndseI49ucY3VSWPaSNwx1x70hxZXkAIZQvA6E1SlYxgBjhj0rVlC5G0fMOtUrhTKflUE9MUmCZVt2bDZ6k9QelOYAjEYO89TU8VqSM7vkPbPNDARhgAaWtwcihKJVVWGOuKRtzptYfL2NWJDvzgYPaqr7mBXODU9RXK8h2Fl5qGM7gMcHNW40IyrgE+tMEAD5Y80WFzEciEnGeO/vUi4iXqcVLkEAAjjqKhuRmM5PHpVbEXuVzN5rcEkUjjoTzntTVAVAAoX1olm8tM4oTuTIZKATg8YqsxwrY6GnySBhz061WlcKCTnB6U7EXEdhHyT2rMuJy8nHSpJ33txxUP8RzQTcjcnPWo3GB71IduSB1qGThuDVJEsjY7VPrVaRvzqWR8E4qtIxLZ6U7GcmNfCjk1l30n92rUrknrWZesmSBya1hExnLQpyPuqKgnJqS3hM8yxr1JrbYxeppaBZefP5rj5FPFdWFAGBxUFhbLbW6ooHSrBrKTuy0tBD0oOfWikNSMfCJDcRLBuMxdRGF67s8Y/HFdUby7h8T3NpfS6PI9yE+0CRT5HnKOM46PngkcZNczaG4gniu7eNmMUq7WC5G/OQv1PpXS3FppV1ePez6br8bu/mPaJb5UsTkgP2BNMDndca8bWLxtSAF6ZT5oHAB9vbGKKNbupr3V7u5uYjBNJJloiMFPRTn2xRSaAfRjNFKprUyA1Z0yLfKxI+lUmOfrW3pEA2Anr6iok9DSlHmkbUEYUDGeK0YcKucc1SjBCctmr1uvHXOK52epDQsW6hZgT3FacqjyuOlUIxuwauzsAigHqKFsUxlvbky7h0FaMC75AWFUrX51wrdK0bYqjc00Dd9jRUKY8dPaqaMHmZVH3eKneRdvBzmobVVyWHXP51TFEbdIQnANSWbP5Z3jA7VK6+YAOmetTxKqxhT16UJajvZEHljG0NgmrMBKrsPQHg1BNC4OQcVNbDOd4wcVUQexaZQUIc5z0rOkd0J4NXSVbAyc+1V5VzLgHK+1EmEQt41J9OM1OMqMMeabETnkfLjANPQkkswyegBoWonoIxEcQIIA7mqKSqd7AnjpnoasXIBXngEdPUVDHbLIuOcdgKHca2ES6IXDsFY+lWY5d4UZB7mqNzZMT6H+E+tTW6lF2uu0ZxxzQm0O3YfPKMMQACOPaqCTGTCBMYzknvVqUfvNvGMdDVaRCsi7ThVqWx9CYqEQAt24rOuNzSnaSMdfetKXDwsAQTj8qzYJGUEleVOCCKUuwLuTw26umWO0YyB60hkWLIVSeOjUokeTbsYY/nUE3yxMXye5ND8hFNnLznK5K9faklcohYrt9qfDMhQMB8zE4HfHamySib5CvJ4pDKxl34BXg96eUEf8PJp0sflnAbA9BUUr/Jgdfej1EByMBQAAMVWvNwHyEbulSIW2MwJ57VFIQy9Bk+tSMqo53EuOKl2A4IpZECoMjHrUbyjpnAx1oEyC5OAdvB9KhZXchucVa2IMHdu9aR2CkYBx9KLCciKNMKSO9MkQHrRPcBOFByeajkmVgBggUrpENsrNH8xYtxnNVrkCXI5wPSrEzKTgHk1E2BGVHpmmS2Vj8oAAyKoXIkaU5PyjtVlAdxYnjsKhnc5JoIbKLSZkIUCmSZ3c9KkEYUljwTUE0gA60xDJGC9DzVeRsHJNIXBJJyD6VC/PuKaJkxWI5OaqzNtBPepnzt96o3EmOO9aJXMpMq3M55VfzrMlYsTk81NcNg471VPWt46I55Mb0610nhyy2p57jlunsKxtMtTdXQXB2Dk120EYjjCgYqZvoEUPopexpKzLEIxTTxTjTTigSRZspZ3lhtY5pkjkmRtsfPz5wGA/vDtXX3EsEOptZSeM9VEofy2byyVDehO71riYJnt7iOeI7ZImDofQjkV250wXMn9oy+GJ/trnzfs4vFRHbrnyz82D1xTAw/EukiA3N3HqEt68U/kXfnptlRyOCeTkHHWiq+pa091ZXdvJb+XeXV1593KT94rkKir2AooGVqVjijGc0yQk1bMhEG+YKPWuqsI9sa4rndLiMlwWP0rqLdcLisps6sPHqXYlBxntVuInIFVEB4xV6DG4A8msmd8dC9aqSTkVZlGQARim2xKk8cVJnzDn0o6DH2kYTLetTtnaWHYU5QroQvGBTVOxMEHmqBD7SRpOew4NWGUR8rn14qG1Kxg8csatw/OCO4oQCw4kI4IPWpt+xsdaRMKGwOackZI5PPbNUrgRzmXqOnUGppM+UCDz7CnE/Kc8kdRVeS4IfYOgpdQH5Yn5c+5qeNdq5zkt3qNJQygMANwxTWLhSo+6OlNAWUG4YXGR1qxDGdmCMsazLKRvMYZz71qRSFTxniqjYmWhQuoiJDyNuKrw/I+UOfQVqXBjkGI84PJJFV3t9gJGQPWhoaZFJl4vTFRlyw5GMDoPWiM+ZIV3cA1YMTJyMHPrRqwbK0a7yztyT3NZ904wE5AJ4IrZJRIyOnsKpSRK7jA6DkZ6VLQKRTmLRx5GDkY96YsZCll6kZwatTMCFUY54OaiuIyo68UmirlCPzjICRgU65YNAUdyoPUCrSAnnHGO9VbkBjlzgDtUsCgsIXawYn0I7UXA2DI4Y+lWg2RnAA6VWkA3neOD3pbDepCzOQu7JbtTmIwQV+akMbZ4IamNL+8K9DQIcV2gnHH86gbbswDk9adK5xjnGKq7CH3MQQewNADmO4d6ospDnuK0I16kDntmorhNxPIGKTC5QjuRvK44qa4lLjOeO2KiaHMgbGB60NtQbT2pO9rEsizznBqKcFsbThRStOMnA4PFRyMUXOOamyIuQiMckMcjiobiZUTbn5qleT5Bgdaz3AdyT2qkhPUc77V4I5FUZHctnORT3YknjAqNm4wBVEMilck45xVKVuTirEpb8KqScDPOaaIbITnOaGbA6U0lskD7tMdsVSRm2RyOQOTWZdTctyM1YunO2sadiW5raMTKTGSMSxpFBY4HLHpSHmtjw9ZedMJmGVU/LWjdkZJXNjRLEW0GWHzEZNagGBQAAMDpS5xWN7loa1JSnk0h60hgab0NKT0phzmgCaymW3v7a4kTekUquy+oByRXRX2k/bdZl1OLXLD7LLKZhcPPtlQZz9zrkdMe1c9b2V1dqxtbW4nVTgmOMsB9cVKujaj50ZOm3nDDk27ev0piDxFeRahrl9d2wIgmlLJkYJHTOO2cZoqfxiAnivVUVQqibAAGAPlFFAyI9KgkPUDrUjnv3qNRvlVcdTTbMzc0OH92CRyea3owMgVQ0qHYg4rThXL9OlZydzvoxtEswJzUqfI/AOM0sQwatFFwDjmsnqdMS5bvlamjjyxJ4qG2VdvHBqRH+cAnimUWrcctgEYpZslBtBz3xTSxCkgcmnxLuyD37U7dAJrUDaDjpU5Ys3ydO9QqPLTGKWyOZcE4ye9NdgZe5AHIPrTfOO4AYP9KdPE0WGU5BqJFHmZPAqr9BLUsxnepB6nuKSSyUsDjNSxLj7uKlDZPIppJkttFS4hVUzg/LyMVPbrujG4Hkd6CpJGaehKPyQVHamrXDURIlWQsuBx2pZsgYjO40glXe2B1psbs8jbfu5otYN9Sa2dSOVpLrcI8fwnpxSsyJnoMDpTIphICvGPSn5AMgiBQkkA5pblgIdoPzY7Uy63Y/dgfQUkYJXLKQTwBQJ9zNNwYpCkinnvQZcAsWx+FTT2gMhzn1zmoUQBSpOccGp1LVmU55HaXcBuj7+1WIjvQEjIPrUbjY3AwDUkfmbDvG36VIMSUryCwAA6elZs+C2FySeoqS7lcSHup6+1QRg53Z70mwQ+Ndvv9KjmXC7zn0xVrcVXOFx6VQv5hHjHA7mkwW4oJ27V4NMW3UEkjBBzk02J/wB3vBzT5Zj5ZPY0lYGQXSEkBfxPtVcnZ0AOParXmDbnGeKpSuGOenNDCNx7uFGWHaqsqkg988ipZNzbc9KjuXEeAPmpMm5XJZV2vwe1V5vmAAIzRPN5kyr6dqRmCnsaBMqbDE5wc81FdTEjGeTU8rk5JNVJME5yKnUm5HIwVOTzVRpAc9s0sp3A5PA7VUYHdjOaogmdlAJqo8uR8ppJpgMqTUAYHlRxTJCViB15qm7Ng5qaWTJqtKxPSqREhpfA681Xkb9KV/U1UuZgB1wPatIozk7FW7mByBWe7ZNS3DjcQpJFQdq3irI55O7JLeJp5VjQcnrXb6dbi2gVQOgxWP4cscKZpFwT0J9K6Psazk7lRQlJR2o6VBQZpKU009KAGnqaSlPWm0Elq01G+sUZLK8uLdWOWETlQT6mpjr+sf8AQVvf+/xqzo8Vnb6PeapfWv23ypkgjhZyqAsCdzEc9sVJc6dZ6hZrqOjRsiROovLJjuMIJ+8p6lD+lMaMGeWSeZ5Z5Gklc5Z2OSx9SaK0PFdvDaeJdSgtkEcEc21EHQDANFAyJyKn0qIyTluwqnK3HXmtzRIcRg45PNJsUFdm9Zx7UzV6Ac1DAoWMDvVyNOhFZs9GCsTwqOKnYAc461CqkEYNWGUumD1FQzVE8RAGAOTU0cRQBjxUUCEMua01XMY9apIL2JYoQY9xoLCPA2jrwaVXKjnoeKaecEjOKpiW5OmHHI5pQgUjAHFEBQhhk5p6hQfvZPvTAsqcxhWxTlQKhLAYqi82xsscHtVqBzKvWqumBKpHHP5VIVBzxzUDo6YI9asqGIzQhMoPKUmKgHJ708FgCWJ+lTSqu84ALVAWOfTJqShkQZ5epUVdhAGRwD7UyNCpIJ5PPSkZmBHIBFWhXEnjMhPOMd6W1UqTjlh60/aDgkH60tuVZjnk0WE2S8HhsDvVSVwzkArnPbtUtyMJ8g9qrx4KnIxTERMSwPQHPU1F5ignHakn4ztO49lNVYXYuVYc+1RcpKwsgLy7hjFOx12nB60rjB+XJz61GXCk9KkpkNxGQQRgZ681UdZMgpggVZlbLZbOPQVHuULnpz0pMVyIrInLYINVJ4/Nbaw4+lXGkLHJ5x2pCwzkjHtRYLtFZQltkKwx2BqvNLlTsPJ9Ksy4k/hqrLGIxkVLQXuMTLwhnbFRIg3Ern3p0AIc9dpp7sFQ4xmixLkQzuEj+bms+SRXPtReu8hYBsfSq6K0a/MMkjNDCxJIFXkd6gaIsSRxillbDAE1FLMVT/CpERScgjpVKbgEZyPWpmLOGPQVRuZP4RmmQQMxZtoHAqKd9rYHX609WYc1VkOXyaaIZBKhbLMeTTQQFwMVJIxJI9KrsMA00jNsbI1VZ5NoJ70+Q8VVnfseTVpEtkMshK5PFZ11JxjFTzyFQQentVCVs5raKMJMjJzVvS7U3VyoxlAcmqagkgDqTgCux0GxFvbqxHzHnNVJ2IjuaUMQijVV4A9KkNFFZGg2g0ppppADdaaac3WmmgBppDjv0pT0pDxQSjV0FtXjW5bSbaW4ikXypkEPmIcjjI9e4NO07TfEWm3SXFlp+oxTJwGEJOR3BHcVBoGo3OnX2bVJJ0mUxy26k/vVPbjofQ9qdcRa9ArSSR6rHCOctv4HuaZRT1uW6uNWu5tQiMV5I+ZY9u3a2Bxjt2oqrLI8rl5GLu3JZjkn8aKAJ4k8ydVHXNdnpsAjjXjpXK6HF5txuxnFdpbqdv4VBtQj1LkQAINWY/QVAi4AxV23UZ5qDrRLAuDk1cCg881UxtyR271PDIzRc96CkWYsbs4zir8I345FUIV+TvVu3ypJPamhtEcjMJQvbNXDgp3FQzDlSRkmrUI3oBjpQkMhTdHJwM1ZC5YN69afgJjJ4NSRsA4GPzqkK5DPamSRQMYYcVdtYfKC9CKlGzaAetRCTy3wMgHrVJWJvcnlb5sYHFKrKRhDz3qGYuV3YzioILoF8DOc4ovqFnYlljO/pye9KYBtHzCn/M8nIxj1qrdyujHGevQUWBFjHB3H6Gq8qbWyBuz3oR2IGc0qqw3DmncpIsoDsUYGP1piKqcEnFRozL1NQSXflNhqCS/Ls2YY96qTEYYDtUUbM8ZJbIPNNmV1IK8D3qbjsRPwxPtUOMgkrhh6d6tKmRljkdaikIB5IxSGMj5zVG9Qg/Ke9X425yMEGoLgHd0GBQwT1IUzs6c1TuSxGCOatSyFUPPNURIS+Scp3qXoNFceYhIIIGc1JPJ8oPOKeWUHOc5NQuSckDr+VAMWNyy5IPFVpyzkhPxqV5NowwGelMbJGU25z3pPUkjgVlGPWqsp2zjdyTWrH5YPPWs+6Km5/WjoTfUhZApZ3wfaqMsgd/lzx6VNL80rAn8M1TmfGVUYqbj0IJVDvkt+FRSsEXkcU8kiqtzkt14oFcSRy6YXiqM4255yamkOF4qmxJY5Jp2IkyKZyKpl8nip53BNVZDjp1poyuMkbng1G7YHWnjpzUMhANWQyGVyBnk1Rnk4PrVmc57/AJVQuZAOlXFGcmVLhyTzVUmnzPubIpIY2mlWNerGttkYPVmnoFn584lf7q9K7BVCqAO1VNNtRb26hQM4xV3FZN3NErITtSd6X2opCuJSHpS803OaBph2pppSOtJntSC40ikPY0pNMJoJOk8MSTNpeoW2l3Mdtq0joUZnCM8QzuVWPQ5xVi00/wAWQXKSm7ltVUgtLPdjywO+ck5HtWXpVtYR6Td6nqkD3UcUqQR26PsBdgTlm7AYp17plpdWkepaP5rWiyKl1aytve3JOM57ofWmUil4iltZtev5bAKLV5SU2jAPqQOwJzRS+KLWGy8R6ja2qbLeGbbGoOcDAooGaXhqDbGCRya6qFKyNIiEcS8YrYU85HasmdtOPKi5EoxnFSJJtBx1pLcZTNP2jPAqWaotQjfFzUsUR6E8Uy3G1Qfxq0DlM9KC0IWEeADxWjEokUdqxZQWYEdK1bF8Dk81UQZeWDpuPA6UvmLESM8HrTBIcjJOKiuTuUmm3bYSV9x0jBjkdOmamiby03HPFVYSu0DParKA7WDde1JMZMLhZNpXmpi4bO/pVO3tinzcZqRiQmW6VQrItoxccDiolgXzSwBXvzS203A4yKnmlUKSDyOtVYm9nYkR8tjggU94kkG4gZPFZ8MhZsg9ane4EY5Jye1MQskYVeOuKpymXeNg5qczB+npioppSqgKNx7mi41ckbdsG5hnvUEsIIJIyKatzuwB949RUrzRgjdxnrRow2I1/dICenao3uN+cYLelLcHfFlcfSqC27xneGIAOT9PSpY9y5ESB069ap3JcNzyKnFyhOxTSXEgwF4OeKA2GwYKDB57VRvppBnHrU0shij+XjFUXPmkBjzSb0BFcSGVsZIqWQBIsjmniEBwRg06ZSq8gYxU2BvUpo4Y4I/Ch5NgwcAZpBznJwfp0qs4LOVzkA0XGSFwwyRzULzFcjBqRRjryMU0p34x70hEbzAJnIz35qnJMWY7SDU11Gqj5AOetUVUIxwOO5pNha+qHOwOePm9arMuCWLU6WdE3DI6VV8zK/ezQSyOZ/mxkVBMOPemyj59xaopZAqdTQQ2RTHAz3qm8nBzTpJCeM1XmYGqM27kLt19Khk4pWbnFRSEjrTRDY12OMVWl6dafK+Bxiqksh9KpakN2GStjPNZl1JyRVi4kbJGeKznYk4JzW0UYykITmt3w5ZFmMzjHYZ9KyLSA3FwsY/Ou6s4BBCqgY4ok+hKJwMDAoNJ3ozmoKQU2nGmtgUFATkCkopCaRLA0hPFGaYaAuB6009DTieaYelIC7puqT6fHcxxCKWC4XbJFMm9W9DjsR2NQ6Vqdxpd0J7GYCUDawI3K691YdxWp4d0+OdWuJYo52aUW8EUpIj37SzO+P4VUZx3qa0vBqC3i3i2FzbW4LmOK3EMhiBw0kTKByBg4PUUxow9UvZNR1K5vZlRJZ33sqDgHGOKKXVbQ6fqFxalhJ5TYD4+8OoP5EUUDO4s02IKvwgF8VXj/wBTVmHoKyZ6SWheiJAwB1qZEO/B6VFB0qyakdrE6rtKgdKsTACIFKhP3F+lWP8AlktNAmQAMqgkA1Zswd3BzVdvvVNb/e/GhFmkq5XjmoJWP3evtT4e1QXP+uX61TEtye1QBiStTmRVkAJ4qNfutTR1H1oWg9y+G3cYBFPEOU5HFQQffX61eP8Aq2q0rmbK4XywoXpUZBbdkkn0qVf9W30pY+op2AjiTY3NSSRBx0496kk7UjdKBXK6xeSc5yPSjCyZAOO9LP8AeSo4+r0DEa3RRuB60yWPcmemKmk/1Ypv/LP8KLCuMhjyvzYFOkAWMgKPxqOHpJ9KiUnd1oAqiBt+4gAE+lQzt5cmAct6GtSb7o+orJvPvn61BS1HMPMhLcfSqLJsJwTmr8f+pFNHU/UUE3I4UygzxmluGVF2kZA6VNL938apXX3WoFbUptIrMQCcUhIz06VCv3WpLj/UH8KRpYe8oC4I6d6pzXQzhcU4/wCprNk/1tS2CRYYkyEk/LVedycgcDpT+zfSoz92kD0My6QE4Jx70yPCx4zzTr7qag/h/CgiWxDcuTlRVKVz0Jq8/wB6qE3+tpmTIZWOAKgkJBxUk336gk600Zt2E+Vck81VlYs1SvVZvvmqSIIn681UkcBjViWqNx0NaIiTKl1JzVQ+tPm+8frSR/6xPrWpi9TpfDtiUTzZB855roarWXEC49BVmsmVawhoHSg9KKATGkUhyaeKaehoKEzTTSikPekSNJ4pKDSHtSAQ0004031oHY2fD+oJAjW00yW7CUXFvM6lkWTBUq4H8LKcH0rQ2WtrHMZI9O0+CZdkslvdm4kdDyUiX+Hd0yegrkxSEAZwBTGWNVvGv9QuLtkEZlfIQHhR0A/AACiqp+6aKQH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bulla is present in the site of an insect bite.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32198=[""].join("\n");
var outline_f31_28_32198=null;
var title_f31_28_32199="Synthetic conjugated estrogens A: Drug information";
var content_f31_28_32199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Synthetic conjugated estrogens A: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/39/1654?source=see_link\">",
"    see \"Synthetic conjugated estrogens A: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cenestin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3275368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cenestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The lowest dose that will control symptoms should be used. Medication should be discontinued as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Menopause, moderate-to-severe vasomotor symptoms:",
"     </b>",
"     Oral: 0.45 mg/day; may be titrated up to 1.25 mg/day; attempts to discontinue medication should be made at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvar and vaginal atrophy:",
"     </b>",
"     Oral: 0.3 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and invasive breast cancer were observed in women &gt;75 years in a WHI substudy using conjugated equine estrogen.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cenestin&reg;: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16360838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms of menopause; treatment of vulvar and vaginal atrophy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F167612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cenestin&reg; may be confused with Senexon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cenestin [U.S., Canada] may be confused with Canesten which is a brand name for clotrimazole [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (11% to 68%), dizziness (11%), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (29%), endometrial thickening (19%), metrorrhagia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9% to 28%), nausea (9% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (8% to 33%), back pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (6%), fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%), vomiting (7%), constipation (6%), diarrhea (6%), weight gain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps (10%), hypertonia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (6% to 8%), cough (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     In addition, the following have been reported with estrogen and/or progestin therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, MI, stroke, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Epilepsy exacerbation, irritability, mental depression, migraine, mood disturbances, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, melasma, pruritus, rash, scalp hair loss, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast cancer, breast enlargement, breast tenderness, glucose tolerance impaired, HDL-cholesterol increased, hyper-/hypocalcemia, LDL-cholesterol decreased, libido changes, serum triglycerides/phospholipids increased, thyroid-binding globulin increased, total thyroid hormone (T",
"     <sub>",
"      4",
"     </sub>",
"     )  increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, bloating, cholecystitis, cholelithiasis, gallbladder disease, pancreatitis, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of menses, cervical secretion changes, endometrial cancer, endometrial hyperplasia, uterine leiomyomata size increased, vaginal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Aggravation of porphyria, antithrombin III and antifactor Xa decreased, fibrinogen levels increased, platelet aggregability and platelet count increased; prothrombin and factors VII, VIII, IX, X increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic hemangiomas enlarged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, chorea, leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature steepening, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions, carbohydrate intolerance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast; estrogen-dependent tumor; hepatic dysfunction or disease; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen plasma concentrations and risk of breast cancer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase estrogen plasma concentrations, leading to increased adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2949101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2949102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk. Use only if clearly needed. Monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cenestin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $399.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45 mg (100): $399.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625 mg (100): $399.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9 mg (100): $399.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $399.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yearly physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cenestin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conjugated A/synthetic estrogens contain a mixture of 9 synthetic estrogen substances, including sodium estrone sulfate, sodium equilin sulfate, sodium 17 alpha-dihydroequilin, sodium 17 alpha-estradiol and sodium 17 beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed over a period of several hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: Sex hormone-binding globulin (SHBG) and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; estradiol is converted to estrone and estriol; also undergoes enterohepatic recirculation; estrone sulfate is the main metabolite in postmenopausal women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily estriol, also as estradiol, estrone, and conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodstein F, Stampfer MJ, Colditz GA, et al, &ldquo;Postmenopausal Hormone Therapy and Mortality,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(25):1769-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/9187066/pubmed\" id=\"9187066\" target=\"_blank\">",
"        9187066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/9718051/pubmed\" id=\"9718051\" target=\"_blank\">",
"        9718051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/28/32199/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10220 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32199=[""].join("\n");
var outline_f31_28_32199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708753\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275368\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167605\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167591\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167592\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837984\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837985\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167570\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167554\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16360838\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167571\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167612\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167603\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167574\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167558\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167600\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167563\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167584\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2949101\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167595\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2949102\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167577\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167568\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301434\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167557\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167573\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/39/1654?source=related_link\">",
"      Synthetic conjugated estrogens A: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_28_32200="Prevention and control of varicella in hospitals";
var content_f31_28_32200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and control of varicella in hospitals",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     David J Weber, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     William A Rutala, PhD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32200/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/28/32200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). Primary VZV infection results in the diffuse vesicular rash of varicella, or chickenpox. Endogenous reactivation of latent VZV typically results in a localized skin infection known as herpes zoster, or shingles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Varicella is generally a mild disease in children, although serious complications can sometimes occur (eg, secondary bacterial skin infections and pneumonia). Complications from VZV infection are more common in neonates, adults, or immunocompromised persons.",
"   </p>",
"   <p>",
"    Following the introduction of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in the United States in 1995, the incidence of varicella has substantially decreased, especially in children one to four years of age. Varicella vaccine has also been successfully employed to prevent or lessen the severity of illness in contacts after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22278?source=see_link\">",
"     \"Epidemiology of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because varicella is highly contagious and may cause serious disease, the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ], the American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/12\">",
"     12",
"    </a>",
"    ], and infectious disease experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ] have published recommendations regarding the isolation of patients with VZV infection and the management of patients and health care workers exposed to VZV.",
"   </p>",
"   <p>",
"    Issues specific to infection control and care of exposed health care workers are discussed below. The epidemiology, clinical manifestations, diagnosis, treatment, and prevention of varicella infection are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22278?source=see_link\">",
"     \"Epidemiology of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF VARICELLA AS A NOSOCOMIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of varicella is important in health care facilities for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella-zoster virus is highly contagious. This is particularly true of patients who present with varicella, compared with those with zoster, who are generally less infectious.",
"     </li>",
"     <li>",
"      Although varicella in healthy adults is often a relatively benign disease, it may be associated with serious complications, such as pneumonia.",
"     </li>",
"     <li>",
"      Severe complications, including death, may occur in immunocompromised patients and neonates.",
"     </li>",
"     <li>",
"      Infection in pregnant women may lead to congenital varicella syndrome or neonatal varicella. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"       \"Varicella-zoster virus infection in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of varicella have changed significantly since the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22278?source=see_link\">",
"     \"Epidemiology of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF VARICELLA TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are the only known hosts of VZV infection. VZV appears to be transmitted primarily person-to-person by the droplet route, and occurs most efficiently when there is close contact. VZV is extremely labile and is therefore unlikely to be transmitted by inanimate objects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of varicella ranges from 8 to 21 days, but most patients develop disease between days 14 and 16. Patients with varicella become infectious 24 to 48 hours prior to the onset of rash. Normal hosts remain infectious for approximately five days after the onset of the rash, while immunocompromised hosts may remain infectious for a more prolonged period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary attack rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary attack rate of varicella among susceptible persons in the household setting is about 85 percent. Comparable data in hospital settings are not available.",
"   </p>",
"   <p>",
"    The reactivation of VZV may lead to herpes zoster, also known as shingles. Herpes zoster is also infectious, although analysis of households suggests that the risk of transmission is only one-third that of varicella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NOSOCOMIAL TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial transmission of VZV is well documented from either persons with clinical varicella infection or reactivation disease with herpes zoster.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transmission from persons with varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella may be introduced into the hospital by patients, staff, or visitors with either clinically evident infection or during the incubation phase of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial varicella has also occurred among staff and patients who had no direct contact with the index case, supporting airborne transmission as a mode of spread. Epidemiologic and tracer studies have confirmed that exposure to airflow, from rooms occupied by patients with varicella, is a major risk factor for the acquisition of infection among susceptible hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ]. One hospital outbreak was attributed to varicella exposure during the course of an autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An outbreak of varicella was also described in a tertiary pediatric facility with an oncology unit. Over approximately 16 days, varicella was detected in seven children (the index case, five secondary cases, and one tertiary case) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the seven identified cases, four appeared to represent \"breakthrough disease\" in previously vaccinated children.",
"   </p>",
"   <p>",
"    In contrast, transmission of varicella in the hospital nursery is rare because of transplacental passage of protective maternal antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transmission from persons with zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to dermatomal or disseminated zoster also has led to clinical varicella in the hospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one long-term care facility, a small outbreak of varicella was reported after a case of herpes zoster was diagnosed in one of the nursing home residents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/17\">",
"       17",
"      </a>",
"      ]. Clinical samples were collected from three case patients; genotypic analysis showed that the identical varicella-zoster strain was present in all three cases. Furthermore, high concentrations of VZV DNA were detected in environmental samples from the room of the herpes zoster case patient. Two of the three patients did not have any known contact with the index case while the third, a health care provider, had changed her linens. This case is notable since the index case was placed on contact precautions within 24 hours, was appropriately diagnosed and treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      , and her rash was covered with gauze and clothing.",
"     </li>",
"     <li>",
"      In another case report, recurrent varicella occurred in a seropositive physician 14 days after examination of an immunocompetent patient with herpes zoster ophthalmicus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/18\">",
"       18",
"      </a>",
"      ]. The physician wore gloves at the time of the encounter but did lift bandages to examine the patient, who had initiated antiviral therapy less than 12 hours previously at this time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These case reports suggest that aerosolized virus from skin lesions, and possibly from the respiratory tract, may cause infection, even in those who have no direct patient contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/19\">",
"     19",
"    </a>",
"    ]. Varicella-zoster virus DNA has been detected by PCR on the surface of gauze dressings and in room air purifier filters, supporting the failure of gauze dressing to completely prevent aerosolization of the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection control measures are addressed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Isolation precautions for patients with zoster'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cost expenditures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The costs associated with VZV outbreaks or overall VZV control have been provided by several investigators. Containment of single outbreaks of VZV infection within a hospital setting have been reported to cost from $9,100 to $19,000 while the costs of one year of VZV control in a hospital have ranged from $41,500 to $63,213 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION OF VARICELLA AMONG HEALTH CARE WORKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rationale for immunizing susceptible health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following groups have recommended that all health care workers be immune to VZV: The Advisory Committee on Immunization",
"    <span class=\"nowrap\">",
"     Practices/CDC",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ] and the Hospital Infections Control Practices Advisory",
"    <span class=\"nowrap\">",
"     Committee/CDC",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/21\">",
"     21",
"    </a>",
"    ], the American Medical Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/22\">",
"     22",
"    </a>",
"    ], and the Canadian National Advisory Committee on Immunization (NACI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compelling reasons to attain seroprotection among health care workers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To decrease transmission from health care workers to hospitalized patients and vice versa.",
"     </li>",
"     <li>",
"      To decrease the risk of severe morbidity and mortality that may occur with varicella infection among adults and immunocompromised patients",
"     </li>",
"     <li>",
"      To avoid the significant costs associated with nosocomial transmission of varicella.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once varicella exposure has been identified, multiple resources within the hospital must be mobilized at considerable cost including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of susceptible staff from patient contact following VZV exposures",
"     </li>",
"     <li>",
"      Administration of prophylaxis to patients and employees",
"     </li>",
"     <li>",
"      Time and effort of hospital staff in evaluating potential VZV exposures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine varicella immunization has been demonstrated to be extremely effective in children and adults with minimal side effects (eg, pain at injection site). In the setting of post-exposure prophylaxis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is associated with both prevention of infection and lessening of disease severity in those who do become ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/24\">",
"     24",
"    </a>",
"    ]. The efficacy data regarding varicella vaccine are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Establishing susceptibility to infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most people, birth before 1980 is considered evidence of immunity, since the prevalence of disease was previously so high. However, in health care providers, age alone is not considered sufficient enough to document immunity; this risk group should have serologic testing or a clear history of prior varicella or varicella vaccination. In fact, the Advisory Committee on Immunization Practices (ACIP) states that \"institutions may elect to test all health care workers regardless of disease history because a small proportion of persons with a positive history of disease might be susceptible\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ]. Others suggest serologic testing only in health care workers with a negative or uncertain history of VZV based on the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A past history of varicella in health care workers is highly correlated with immunity as measured by serology; less than 2 percent of health care workers with a positive history of varicella are susceptible to infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, reported serosusceptibility among hospital personnel with a negative or uncertain history of VZV infection has been higher (eg, 15 to 30 percent). Following nosocomial exposure to varicella, approximately 2 to 30 percent of susceptible staff have developed clinical infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13,25\">",
"       13,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health care workers should be screened for VZV immunity (by history or by serologic testing) at the time of initial employment, as is currently recommended for mumps, measles, rubella, and hepatitis B. Multiple serologic tests have been used to detect VZV antibodies; the preferred test is a latex agglutination (LA) test. Other test methods include enzyme linked immune-absorbent assay (ELISA), indirect fluorescent antibodies (IFA), and radioimmunoassay (RIA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Active immunization of susceptible health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;All susceptible health care workers without a contraindication to immunization should be vaccinated. Employees without a definitive history of VZV infection should undergo serologic testing, and if negative, be immunized (",
"    <a class=\"graphic graphic_table graphicRef54971 \" href=\"mobipreview.htm?11/24/11660\">",
"     table 1",
"    </a>",
"    ). Contraindications for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cost-effectiveness studies have demonstrated that immunization of health care workers susceptible to varicella is cost-effective for health care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. At UNC Hospitals, this immunization requirement also extends to hospital employees without direct patient contact (eg, security officers, students, and contract employees).",
"   </p>",
"   <p>",
"    Health care workers caring for immunocompromised hosts can receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    since the risk of transmission of vaccine strain virus is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/28\">",
"     28",
"    </a>",
"    ]. The American Academy of Pediatrics, the CDC, and the ACIP do not recommend any specific precautions for immunized health care workers, except in the event that the vaccine recipient develops skin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Management of exposed susceptible health care workers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ], the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/12\">",
"     12",
"    </a>",
"    ], and infectious disease experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ] have published guidelines or algorithms designed to aid clinicians in the control of nosocomial exposures. The guideline used by the UNC Hospitals is displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef52900 \" href=\"mobipreview.htm?17/17/17693\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Isolation precautions for patients with varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC has recommended that all patients with varicella be placed on airborne plus contact isolation precautions. Airborne isolation (as is used for pulmonary tuberculosis) requires:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative pressure of room with respect to corridor",
"     </li>",
"     <li>",
"      Greater than six air exchanges per hour",
"     </li>",
"     <li>",
"      Air is exhausted directly to the outside",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We are unaware of any nosocomial outbreaks related to infected patients who were placed in private rooms with negative pressure. However, given the current incidence of tuberculosis, it is likely that many hospitals do not have an adequate number of rooms meeting the OSHA tuberculosis requirements to use these rooms to isolate patients with VZV infections.",
"   </p>",
"   <p>",
"    One report documented a case of varicella occurring in a susceptible employee who never entered the patient's isolation room, but remained in the outside corridor passing materials in through an open door [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/30\">",
"     30",
"    </a>",
"    ]. This incident emphasizes the need for strict observation of airborne precautions, as recommended by the CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For exposed serosusceptible patients, the Centers for Disease Control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ] and the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/12\">",
"     12",
"    </a>",
"    ] suggest isolation for 8 to 21 days after exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isolation precautions for patients with zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends that all patients with disseminated zoster and immunocompromised patients with dermatomal zoster be placed in private rooms meeting standards for isolation of tuberculosis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ]. Information about these isolation requirements is discussed above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Isolation precautions for patients with varicella'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, the CDC recommends that immunocompetent patients with dermatomal zoster be placed on contact precautions alone as opposed to both airborne and contact isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ]. However, UNC Hospitals places",
"    <strong>",
"     all",
"    </strong>",
"    patients (immunosuppressed and immunocompetent patients) with dermatomal zoster on airborne and contact isolation because of reports of suspected airborne or droplet transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As noted above, both environmental sampling of varicella DNA by PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/20\">",
"     20",
"    </a>",
"    ] and various clinical outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/17\">",
"     17",
"    </a>",
"    ] suggest that covering herpes zoster lesions with gauze is inadequate to prevent aerosolization of varicella virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION OF EXPOSURE AMONG EMPLOYEES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All employees potentially exposed to varicella or zoster should be evaluated as soon as feasible by the Occupational Health Service (",
"    <a class=\"graphic graphic_table graphicRef81320 \" href=\"mobipreview.htm?3/48/3852\">",
"     table 3",
"    </a>",
"    ). VZV infection in the source patient should be confirmed.",
"   </p>",
"   <p>",
"    In all potential exposures, the potential for VZV acquisition should be assessed. UNC Hospitals defines VZV exposure as being within a confined airspace (ie, same room) or prolonged face-to-face contact with an infectious patient by a susceptible employee who did not wear a respirator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXPOSED PREVIOUSLY VACCINATED HEALTH CARE WORKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends that exposed health care workers previously immunized with two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    should be monitored daily during days 10 to 21 after exposure through the employee health program or by an infection control nurse to determine clinical status (ie, daily screen for fever, skin lesions, and systemic symptoms). They further recommend that health care workers should be immediately placed on sick leave if symptoms occur.",
"   </p>",
"   <p>",
"    Since it is highly impractical to examine health care workers daily, at UNC we inform exposed susceptible health care workers who have been vaccinated to perform self evaluations and report (by phone) any symptoms or signs suggestive of varicella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXPOSED SUSCEPTIBLE HEALTH CARE WORKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, all health care workers are screened for evidence of varicella immunity at the initiation of employment, and immunization is offered to susceptible health care workers (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Active immunization of susceptible health care workers'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Susceptible health care workers may not have been vaccinated at the beginning of employment because of medical contraindications or due to nonadherence to immunization procedures and policies. These individuals may need post-exposure prophylaxis; the type of prophylaxis will depend on the specific circumstances surrounding lack of prior immunization. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Post-exposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Health care workers who have a clear history of varicella or who are seropositive for varicella are not at risk of reinfection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prevention of varicella among health care workers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Work furlough",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some differences in the days of furlough recommended by various guideline committees. The ACIP suggests that exposed serosusceptible employees be removed from work from days 10 through 21 postexposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ]. In comparison, the Centers for Disease Control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/11\">",
"     11",
"    </a>",
"    ] and the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/12\">",
"     12",
"    </a>",
"    ] suggest that employees be furloughed from days 8 through 21 after exposure.",
"   </p>",
"   <p>",
"    Furlough is recommended regardless of what post-exposure prophylaxis the susceptible health care worker is taking (including vaccine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-exposure prophylaxis for health care workers may include the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . Other less commonly used interventions include VariZIG or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . The appropriate situations for the use of these various interventions is discussed below.",
"   </p>",
"   <p>",
"    A potential concern in using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    as postexposure prophylaxis is that if the health care worker develops a rash consistent with varicella it is impossible to determine if this is due to wild-type virus or vaccine strain. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Varicella vaccine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP has recommended that health care workers exposed to varicella-zoster who are unvaccinated or have received only a single dose of vaccine be provided post-exposure vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. The vaccine is most effective when administered within three to five days of exposure.",
"   </p>",
"   <p>",
"    In a double-blind, placebo-controlled study, the Merck",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    was reported to be 67 percent effective in completely preventing illness and 100 percent effective in modifying varicella severity when administered within five days of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"     13",
"    </a>",
"    ]. However, immunization is still indicated even if given more than five days after exposure, because vaccination induces protection against subsequent exposures.",
"   </p>",
"   <p>",
"    The risk of transmission of the vaccine strain from health care workers to susceptible contacts of immunized persons appears to be very low in immunocompetent persons. Healthy household contacts of immunocompromised patients can receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    since the risk of transmission is also low in this situation as well. By analogy, health care workers can still receive varicella vaccine if they work with immunocompromised patients. To date, no cases of vaccine virus transmission from an immunized health care worker to a susceptible patient have been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ]. For a detailed discussion, see related topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians need to be aware that a vesicular rash can sometimes follow",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . Rashes that occur within the first two weeks after immunization are usually due to wild-type varicella whereas rashes occurring 15 to 42 days after vaccination are more likely due to vaccine-associated virus (ie, Oka VZV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/31\">",
"     31",
"    </a>",
"    ]. Transmission of wild-type virus is much more common than vaccine-associated virus; however, there are no commercially available laboratories to distinguish between the two possibilities. In either instance, a health care worker with a vesicular rash following varicella vaccine should be furloughed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     VariZIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed seronegative health care workers who did not receive vaccine at the initiation of employment because of medical contraindications and are immunocompromised or pregnant should be considered for VariZIG, which became available under an investigational new drug application submitted to the FDA in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/32\">",
"     32",
"    </a>",
"    ]. The availability of this product has assumed more significance, as the supplies of the previously used VZIG are no longer available because the manufacturer ceased its production. The recommended dose is 125",
"    <span class=\"nowrap\">",
"     units/10",
"    </span>",
"    kg of body weight, up to a maximum of 625 units (five vials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ]. The minimum dose is 125 U. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Health care workers who receive VariZIG should be furloughed from day 8 through day 28 postexposure, as VariZIG may ameliorate, but not prevent, varicella. Antiviral therapy should be initiated in any person who develops signs of varicella disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends VariZIG for postexposure prophylaxis of immunocompromised persons and neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"     9",
"    </a>",
"    ]. However, if VariZIG is unavailable, several small studies in healthy children and those with leukemia suggest that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , initiated within three to seven days after exposure and continued through the incubation period, is effective in lessening disease severity and may prevent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Follow-up serologic testing should be performed for any health care worker who receives post-exposure prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    to determine if the patient has seroconverted; receipt of prophylaxis does not eliminate the possibility of varicella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is not indicated for prophylactic use among otherwise healthy adults without evidence of immunity after exposure to varicella, except in the pregnant patient. Immunization with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is the method of choice in these situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Documentation of varicella immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard guidelines should be practiced for varicella immunization, including assessment of contraindications and precautions, medical record documentation, and informed consent. The following information should be recorded in the medical record: employee name, date, vaccine, manufacturer, lot number, site of immunization, and informed consent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adverse events of vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States significant adverse reactions should be reported to the Food and Drug Administration (FDA) via the vaccine adverse events reporting system (VAERS). Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Assessment of immunity after immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postimmunization serology is not recommended since:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Commercial tests may lack the sensitivity to detect the lower antibody levels associated with vaccination compared with natural infection.",
"     </li>",
"     <li>",
"      Studies suggest a seroconversion rate of 99 percent in adults after two doses of the",
"      <span class=\"nowrap\">",
"       Oka/Merck",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (VARIVAX) administered four to eight weeks apart in adults (",
"      <a class=\"graphic graphic_table graphicRef78824 \" href=\"mobipreview.htm?5/16/5389\">",
"       table 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32200/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HEALTH CARE WORKERS WITH VARICELLA INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Diagnosis of varicella in health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;History and physical examination alone are usually sufficient to diagnose varicella or zoster; however, vesicular fluid can be sent for culture or PCR analysis if any uncertainty regarding the diagnosis exists or laboratory confirmation is desired.",
"   </p>",
"   <p>",
"    All health care workers with VZV infection should be evaluated by the Occupational Health Service. Following confirmation of infection, staff and patients exposed to the health care worker should be appropriately managed (",
"    <a class=\"graphic graphic_table graphicRef52900 \" href=\"mobipreview.htm?17/17/17693\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All health care workers should be offered antiviral therapy, which should be initiated within 72 hours of the onset of clinical infection. Treatment recommendations for healthy adults and women during pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Return to work",
"    </span>",
"    &nbsp;&mdash;&nbsp;Employees who develop varicella may return to work when clinically well and after all lesions are dried and crusted (usually about five days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella-zoster virus infection is the causative agent of two diseases: varicella (chickenpox), the primary infection; and herpes zoster (shingles), an illness due to reactivation of latent VZV infection. Varicella is generally a mild disease in children, but can cause serious infection in neonates, adults, or immunocompromised persons. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of varicella is important in health care facilities since varicella-zoster virus is highly contagious. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Importance of varicella as a nosocomial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period of varicella ranges from 8 to 21 days, but most patients develop disease between days 14 and 16. Patients with varicella become infectious 24 to 48 hours prior to the onset of rash. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles of varicella transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial transmission of VZV is well documented from either persons with clinical varicella infection or shingles, although the rates of transmission are much higher from patients with varicella. VZV appears to be transmitted primarily person-to-person by the droplet route and occurs most efficiently when there is close contact. &nbsp;(See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nosocomial transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial varicella has also occurred among staff and patients who had no direct contact with the index case, supporting airborne transmission as a mode of spread. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nosocomial transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lack of susceptibility can be established by a clear history of prior infection, past immunization, or serologic testing. All other health care workers should be assumed to be susceptible to infection (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of varicella among health care workers'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We recommend that all susceptible health care workers should be vaccinated, unless there is a contraindication to immunization, as advised by the ACIP (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of varicella among health care workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lack of susceptibility can be established by a clear history of prior infection, past immunization, or serologic testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of varicella among health care workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with varicella or disseminated zoster and immunocompromised patients with dermatomal zoster should be placed in private rooms meeting standards for isolation of tuberculosis patients, as advised by the CDC, whenever possible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition, contact precautions should be used as well. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Infection control measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CDC recommends only contact precautions for patients with dermatomal herpes zoster infection. However, due to case reports of nosocomial outbreaks where no contact has been reported, we suggest airborne and contact precautions for patients with dermatomal herpes zoster (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Infection control measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposed health care workers who were previously immunized with two doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      should be monitored 10 to 21 days after exposure for symptoms of infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of exposed previously vaccinated health care workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposed susceptible health care workers should be furloughed from work, regardless of the type of prophylaxis they received. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of exposed susceptible health care workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All susceptible health care workers exposed to varicella-zoster require post-exposure prophylaxis, as suggested by the ACIP guidelines. For health care workers without contraindications to vaccination, we recommend vaccination rather than VariZIG or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;VariZIG and acyclovir are suitable alternatives for health care workers with contraindications to vaccination, such as immunosuppression or pregnancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of exposed susceptible health care workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postimmunization serology is not required after immunization. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of exposed susceptible health care workers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Varicella-Zoster Virus, Arvin AM, Gershon AA (Eds), Cambridge University Press, Cambridge, UK 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/2\">",
"      English R. Varicella. Pediatr Rev 2003; 24:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/3\">",
"      Dwyer DE, Cunningham AL. 10: Herpes simplex and varicella-zoster virus infections. Med J Aust 2002; 177:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/4\">",
"      Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 2003; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/5\">",
"      Hambleton S. Chickenpox. Curr Opin Infect Dis 2005; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/6\">",
"      Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/7\">",
"      Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007; 57:S130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/8\">",
"      Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008; 9:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/9\">",
"      Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56(RR-4):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/10\">",
"      Adler AL, Casper C, Boeckh M, et al. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infect Control Hosp Epidemiol 2008; 29:866.",
"     </a>",
"    </li>",
"    <li>",
"     Seigel JD, Reinhart E, Jackson M, Chiarella L. The Healthcare Infection Control Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, June 2007. file://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf (Accessed on February 09, 2012).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella-zoster infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/13\">",
"      Weber DJ, Rutala WA, Hamilton H. Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol 1996; 17:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/14\">",
"      Paul N, Jacob ME. An outbreak of cadaver-acquired chickenpox in a health care setting. Clin Infect Dis 2006; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/15\">",
"      Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/16\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol 2001; 63:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/17\">",
"      Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/18\">",
"      Johnson JA, Bloch KC, Dang BN. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin Infect Dis 2011; 52:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/19\">",
"      Breuer J. Herpes zoster: new insights provide an important wake-up call for management of nosocomial transmission. J Infect Dis 2008; 197:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/20\">",
"      Suzuki K, Yoshikawa T, Tomitaka A, et al. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis 2004; 189:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/21\">",
"      Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998; 19:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/22\">",
"      Lyznicki JM, Bezman RJ, Genel M. Report of the Council on Scientific Affairs, American Medical Association: immunization of healthcare workers with varicella vaccine. Infect Control Hosp Epidemiol 1998; 19:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/23\">",
"      Top 10 health stories of 2004. Harv Health Lett 2004; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/24\">",
"      Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998; 17:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/25\">",
"      Langley JM, Hanakowski M. Variation in risk for nosocomial chickenpox after inadvertent exposure. J Hosp Infect 2000; 44:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/26\">",
"      Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol 1997; 18:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/27\">",
"      O'Neill J, Buttery J. Varicella and paediatric staff: current practice and vaccine cost-effectiveness. J Hosp Infect 2003; 53:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/28\">",
"      Kappagoda C, Shaw P, Burgess M, et al. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 1999; 35:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/29\">",
"      Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/30\">",
"      Tang JW, Eames I, Li Y, et al. Door-opening motion can potentially lead to a transient breakdown in negative-pressure isolation conditions: the importance of vorticity and buoyancy airflows. J Hosp Infect 2005; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/31\">",
"      Breuer J, Schmid DS. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis 2008; 197 Suppl 2:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/33\">",
"      Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/34\">",
"      Lin TY, Huang YC, Ning HC, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/35\">",
"      Ishida Y, Tauchi H, Higaki A, et al. Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir. Pediatrics 1996; 97:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32200/abstract/36\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4047 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32200=[""].join("\n");
var outline_f31_28_32200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF VARICELLA AS A NOSOCOMIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES OF VARICELLA TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary attack rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NOSOCOMIAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transmission from persons with varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transmission from persons with zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cost expenditures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION OF VARICELLA AMONG HEALTH CARE WORKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rationale for immunizing susceptible health care workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Establishing susceptibility to infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Active immunization of susceptible health care workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INFECTION CONTROL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Isolation precautions for patients with varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isolation precautions for patients with zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION OF EXPOSURE AMONG EMPLOYEES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF EXPOSED PREVIOUSLY VACCINATED HEALTH CARE WORKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT OF EXPOSED SUSCEPTIBLE HEALTH CARE WORKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Work furlough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - VariZIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Documentation of varicella immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adverse events of vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Assessment of immunity after immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT OF HEALTH CARE WORKERS WITH VARICELLA INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Diagnosis of varicella in health care workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Return to work",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/4047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4047|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/24/11660\" title=\"table 1\">",
"      Preexposure eval HCW VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/17/17693\" title=\"table 2\">",
"      Management nosocomial VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/48/3852\" title=\"table 3\">",
"      Postexposure eval HCW VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/16/5389\" title=\"table 4\">",
"      Varicella vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22278?source=related_link\">",
"      Epidemiology of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_28_32201="Taeniasis eggs";
var content_f31_28_32201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Taeniasis eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B)",
"    <em>",
"     Taenia",
"    </em>",
"    spp eggs in unstained wet mounts. Four hooks can clearly be seen in figure A.",
"    <br>",
"     (C) Cross-section of a proglottid of",
"     <em>",
"      Taenia",
"     </em>",
"     spp, stained with hematoxylin and eosin (H&amp;E). Note the thick outer tegument and the loose parenchyma filling the body. Calcareous corpuscles (red arrows), characteristic of the cestodes, can be seen in the parenchyma. Eggs (blue arrows) can also be seen.",
"     <br>",
"      (D) Higher magnification of figure C showing a close-up of the eggs. Note the characteristic striations, typical for the taeniids. Not visible in these images are the hooks commonly seen in cestode eggs. Hooks do not stain with H&amp;E but are refractile and visible with fine focusing of the microscope.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Taeniasis. Available at:",
"       <a href=\"file://dpd.cdc.gov/dpdx/html/Taeniasis.htm\" target=\"_blank\">",
"        file://dpd.cdc.gov/dpdx/html/Taeniasis.htm",
"       </a>",
"       .",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32201=[""].join("\n");
var outline_f31_28_32201=null;
var title_f31_28_32202="Prognosis and treatment of essential thrombocythemia";
var content_f31_28_32202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of essential thrombocythemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/28/32202/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/28/32202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic,",
"    <span class=\"nowrap\">",
"     Bcr/Abl-negative",
"    </span>",
"    myeloproliferative neoplasms (MPN, MPD) include polycythemia vera (PV), primary myelofibrosis (PMF, AMM, MMM, chronic idiopathic myelofibrosis), and essential thrombocythemia (ET, primary or essential thrombocytosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/1\">",
"     1",
"    </a>",
"    ]. Other members of MPN include chronic myeloid leukemia (CML), chronic neutrophilic leukemia, systemic mastocytosis, chronic eosinophilic leukemia-not otherwise specified and MPN-unclassifiable.",
"   </p>",
"   <p>",
"    The MPD are themselves a subcategory of chronic myeloid disorders that also include chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS),",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     myeloid/lymphoid",
"    </span>",
"    malignancies associated with eosinophilia and rearrangements of PDGFRA, PDGFRB or FGFR1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ET is neither a cytogenetically nor a morphologically defined disease entity, but rather is a diagnosis of exclusion. Thus, the diagnosis of ET requires that both reactive thrombocytosis and other chronic myeloid disorders have been excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/2\">",
"     2",
"    </a>",
"    ]. This review will discuss the prognosis and treatment of ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The general approach to the patient with an elevated platelet count and the diagnosis and clinical manifestations of ET are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=see_link\">",
"     \"Approach to the patient with thrombocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ET enjoy a normal life expectancy without associated disease-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In morphologically and cytogenetically defined ET (ie, patients in whom PV, CML, MDS, and PMF have been excluded), the delayed development of either acute myeloid leukemia (AML) or post-ET myelofibrosis (post-ET MF) is unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large retrospective study of 435 patients with ET, the 15-year cumulative risks of thrombosis and clonal evolution into either AML or post-ET MF were 17, 2, and 4 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an international study of 891 patients with ET confirmed by the use of WHO criteria, 15-year cumulative risks of thrombosis, leukemic transformation, or overt fibrotic progression were 22, 2, and 9 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/9\">",
"       9",
"      </a>",
"      ]. Overall survival (median survival: 14.7 years) was similar to that of the sex- and age-standardized European population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our series of 605 patients with ET followed for a median of seven years, there were 155 deaths (26 percent). On multivariate analysis, risk factors for inferior survival included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low hemoglobin level (&lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in females and &lt;13.5 in males)",
"     </li>",
"     <li>",
"      Age &ge;60 years",
"     </li>",
"     <li>",
"      Leukocyte count",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Smoking, diabetes mellitus, prior venous thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A simplified model that included only age and white blood cell count at the time of diagnosis found the following three risk groups and median survivals (",
"    <a class=\"graphic graphic_figure graphicRef79360 \" href=\"mobipreview.htm?10/0/10255\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (age &lt;60 and WBC",
"      <span class=\"nowrap\">",
"       &lt;15,000/microL)",
"      </span>",
"      &mdash; 25 years",
"     </li>",
"     <li>",
"      Intermediate risk (age &ge;60 or WBC &ge;15,000) &mdash; 17 years",
"     </li>",
"     <li>",
"      High risk (age &ge;60 and WBC &ge;15,000) &mdash; 10 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23741552\">",
"    <span class=\"h3\">",
"     International Prognostic Score",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472315\">",
"    <span class=\"h4\">",
"     Overall survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;An International Prognostic Score for Essential thrombocythemia (IPSET) was derived from 891 patients diagnosed strictly according to WHO criteria and was validated in two independent cohorts. Scoring was as follows: age &ge;60: 2 points; white blood cell count",
"    <span class=\"nowrap\">",
"     &ge;11,000/microL:",
"    </span>",
"    1 point; history of thrombosis: 1 point. Median survivals were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (total score zero): not reached",
"     </li>",
"     <li>",
"      Intermediate risk (total score 1 or 2): 24.5 years",
"     </li>",
"     <li>",
"      High risk (total score 3 or 4): 13.8 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 10-year thrombosis-free survival of those in the low, intermediate, and high risk groups were 89, 84, and 69 percent, respectively. The IPSET categories did not predict for evolution into myelofibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472322\">",
"    <span class=\"h4\">",
"     Thrombotic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation of this cohort of 891 subjects with ET identified the following independent risk factors for thrombosis (ie, the IPSET-thrombosis model) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60 years (HR 1.5; 1 point)",
"     </li>",
"     <li>",
"      History of thrombosis (HR 1.9; 2 points)",
"     </li>",
"     <li>",
"      Presence of cardiovascular risk factors (diabetes, hypertension, smoking, HR 1.6; 1 point)",
"     </li>",
"     <li>",
"      Presence of the JAK2 V617F mutation (HR 2.0; 2 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using this model, three thrombosis risk groups were determined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk for thrombosis (total score zero or 1): 1.03",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      risk of thrombosis",
"     </li>",
"     <li>",
"      Intermediate risk (total score 2): 2.35",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"     </li>",
"     <li>",
"      High risk (total score &gt;2): 3.56",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for thrombosis and hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk stratification in ET is primarily based upon factors that influence the occurrence of thrombotic, rather than hemorrhagic, complications (",
"    <a class=\"graphic graphic_table graphicRef79467 \" href=\"mobipreview.htm?3/29/3547\">",
"     table 1",
"    </a>",
"    ). In a case-control study reported in 1990, the overall risk of thrombotic episodes in patients with ET was 6.6",
"    <span class=\"nowrap\">",
"     percent/patient-year",
"    </span>",
"    compared with 1.2",
"    <span class=\"nowrap\">",
"     percent/patient-year",
"    </span>",
"    in the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/14\">",
"     14",
"    </a>",
"    ]. Corresponding risks for hemorrhagic complications were much lower, being 0.33 and zero",
"    <span class=\"nowrap\">",
"     percent/patient-year,",
"    </span>",
"    respectively. Significant risk factors for thrombosis in this group of patients were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of prior thrombosis (risk = 31.4",
"      <span class=\"nowrap\">",
"       percent/patient-year)",
"      </span>",
"     </li>",
"     <li>",
"      Age over 60 years (risk = 15.1",
"      <span class=\"nowrap\">",
"       percent/patient-year)",
"      </span>",
"     </li>",
"     <li>",
"      Prolonged exposure to substantial degrees of thrombocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472342\">",
"    <span class=\"h3\">",
"     Prior thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our subsequent experience as well as that of many other investigators supports the adverse prognostic value of a history of prior thrombosis in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. Our latest estimate of thrombotic risk, the IPSET-thrombosis model (see above), includes prior thrombosis as a significant risk factor, although the observed thrombotic risk in this newer cohort (1.9 percent per year) is considerably lower than that reported in the 1990 study quoted above (6.6 percent per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/14\">",
"     14",
"    </a>",
"    ]. Recurrent thrombosis occurred in 45 and 13 percent of our series of young women with ET who had a positive or a negative history of prior thrombosis, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17\">",
"     17",
"    </a>",
"    ]. The corresponding figures in an unselected group of 103 patients with ET were 57 and 16 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472349\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse prognostic value of increased age has not been uniformly appreciated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,15,18\">",
"     8,15,18",
"    </a>",
"    ]. In one study, for example, the risk of a thrombotic event was 1.7 and 15.1",
"    <span class=\"nowrap\">",
"     percent/patient-year",
"    </span>",
"    for patients &lt;40 and &gt;60 years of age, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/14\">",
"     14",
"    </a>",
"    ], while in a second report, the hazard ratio for thrombosis in subjects &gt;60, in comparison to those &lt;60, was 2.99 (95% CI 1.19-7.51) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/16\">",
"     16",
"    </a>",
"    ]. Age &gt;60 years was found to be a significant risk factor for thrombosis in the IPSET-thrombosis model discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472363\">",
"    <span class=\"h3\">",
"     Cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of cardiovascular risk factors in the occurrence of thrombosis has been disputed in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], although smoking, diabetes, and hypertension were implicated as significant risk factors in the IPSET-thrombosis model.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472370\">",
"    <span class=\"h3\">",
"     Leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis, either at baseline or developing over time, has been considered as an independent risk factor for thrombotic complications in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/11,16,21-28\">",
"     11,16,21-28",
"    </a>",
"    ], although these observations are confounded by treatment effect, prior thrombotic history, and the presence of other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472415\">",
"    <span class=\"h3\">",
"     Thrombocytosis and platelet function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, neither the degree of thrombocytosis nor the presence of platelet function abnormalities has been correlated with thrombotic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,16,18,21,31\">",
"     8,16,18,21,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472478\">",
"    <span class=\"h3\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of major bleeding episodes during the entire clinical course of the disease is less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,14,17\">",
"     8,14,17",
"    </a>",
"    ], and is probably not exacerbated following the use of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (eg, 40 to 100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    especially if these doses are used in patients with a platelet count",
"    <span class=\"nowrap\">",
"     &lt;1,000,000/microL,",
"    </span>",
"    the absence of a prior history of bleeding,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acquired von Willebrand disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5472486\">",
"    <span class=\"h2\">",
"     Thrombo-hemorrhagic risk model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, we have developed a risk stratification model for ET for the development of thrombo-hemorrhagic complications. All patients fall into one of the following two risk groups (",
"    <a class=\"graphic graphic_table graphicRef79467 \" href=\"mobipreview.htm?3/29/3547\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to qualify for low risk disease, the patient with ET must have",
"    <strong>",
"     all",
"    </strong>",
"    of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;60 years",
"     </li>",
"     <li>",
"      No previous history of thrombosis",
"     </li>",
"     <li>",
"      Platelet count &lt;1",
"      <span class=\"nowrap\">",
"       million/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are otherwise considered to be low risk but have a platelet count &gt;1",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    should be screened for the presence of acquired von Willebrand disease by obtaining a ristocetin cofactor activity before treatment with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is considered (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Low risk patients with high platelet counts'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A prospective study of 65",
"    <strong>",
"     untreated",
"    </strong>",
"    low risk patients (criteria as above) has validated the low complication rate in this group of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/34\">",
"     34",
"    </a>",
"    ]. The incidence of thrombosis over a median follow-up period of 4.1 years was 1.9 and 1.5 cases per 100 patient-years in the low risk group and the age- and sex-matched controls, respectively. Only three minor hemorrhagic episodes occurred in the patient group; pregnancy and surgery were not associated with thrombotic complications in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     High risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ET are considered to be at high risk if they have",
"    <strong>",
"     one or both",
"    </strong>",
"    of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;60 years",
"     </li>",
"     <li>",
"      A previous history of thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leukemic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our series of 605 patients with ET followed for a median of seven years, leukemic transformation (LT) was documented in 20 (3.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/10\">",
"     10",
"    </a>",
"    ]. On multivariate analysis, risk factors for the development of LT included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low hemoglobin level (&lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in females, &lt;13.5 in males)",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;1,000,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Increased age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A model for the risk of LT was devised using the first two of these factors. Patients with none, one, or both of these adverse factors had a risk of developing LT of 0.4, 4.8, and 6.5 percent, respectively. Use of cytoreductive therapy or presence of the JAK2 mutation did not affect the risk of LT. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Leukemogenicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once transformation to AML or myelodysplasia has occurred in a patient with MPN (eg, ET, PV, PMF), the long-term prognosis is poor, with median survivals in the range of two to seven months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/35\">",
"     35",
"    </a>",
"    ]. However, in one study in 21 patients with ET who developed MDS or AML and were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    (initial dose: 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    subcutaneously for 7 days every 28 days), the overall response rate was 71 percent, with a median survival of 16 months from the onset of treatment with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=see_link&amp;anchor=H6#H6\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Acute leukemia/MDS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most patients with ET enjoy a normal life expectancy, treatment is required for the following complications of ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/4,36-38\">",
"     4,36-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent symptoms are vasomotor, and are easily manageable with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (ASA, 40 to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Vasomotor symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombotic events in low-risk patients with ET are too infrequent to justify the long-term use of potentially harmful agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/19,34\">",
"       19,34",
"      </a>",
"      ]. The risk may be higher, however, in the presence of cardiovascular risk factors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extreme uncontrolled thrombocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/19,20,41\">",
"       19,20,41",
"      </a>",
"      ]. Whether drug therapy is indicated in this particular situation remains controversial. On the other hand, approximately 20 percent of patients with ET present with major thrombotic events and another 15 percent may experience recurrent thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,19\">",
"       8,19",
"      </a>",
"      ]; this complication is most common in patients &gt;60 years of age. Therefore, cytoreductive therapy is indicated in these high-risk patients (ie, age &gt;60 years or history of prior thrombosis).",
"     </li>",
"     <li>",
"      Bleeding complications are less frequent and may be prevented by the avoidance of doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      greater than 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and avoiding the use of nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/18,42\">",
"       18,42",
"      </a>",
"      ]. In regard to spontaneous bleeding, control of thrombocytosis, especially in the presence of acquired von Willebrand disease, may alleviate a bleeding diathesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"       \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapeutic agents available for the treatment of ET are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized study involving 114 patients with ET, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU, Hydrea), compared with no treatment, was shown to reduce the risk of thrombosis in high-risk patients from 24 percent to &lt;4 percent at a median follow-up of 27 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/44\">",
"     44",
"    </a>",
"    ]. In this study, there was only one episode of minor gastrointestinal bleeding in hydroxyurea-treated patients.",
"   </p>",
"   <p>",
"    In a second trial, 809 patients with ET were randomly assigned to receive treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    , both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/45\">",
"     45",
"    </a>",
"    ]. Results of this trial, which reported the superiority of hydroxyurea plus aspirin, are discussed below (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Anagrelide versus hydroxyurea'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Maintenance of the platelet count",
"    <span class=\"nowrap\">",
"     &lt;400,000/microL",
"    </span>",
"    may be associated with further reduction in thrombotic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,46\">",
"     8,46",
"    </a>",
"    ]. The controversy regarding the possible leukemogenic effect of HU is discussed in a separate section (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Leukemogenicity'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The recommended initial dose of HU is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO, taken in divided doses. Doses are then adjusted up or down depending upon the balance between the desired effect on the platelet count, which should be kept in the range of 100,000 to",
"    <span class=\"nowrap\">",
"     400,000/microL,",
"    </span>",
"    and undesired effects such as neutropenia and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4775465\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of HU are usually minimal and include oral ulcers, hyperpigmentation, skin rash, and nail changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/47\">",
"     47",
"    </a>",
"    ]. A small percentage will develop leg ulcers, nausea, diarrhea, or alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 993 consecutive patients with myeloproliferative neoplasms treated with HU (50 percent with ET), mucocutaneous toxicity was reported in 51 (8.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/49\">",
"     49",
"    </a>",
"    ]. This included painful skin ulcers mainly in the perimalleolar area, oral aphthous ulcers, or erythema and skin infiltration. Oral aphthous ulcers were found to be an early toxicity (median time to onset from start of HU therapy: 2.1 months), while skin ulcers and",
"    <span class=\"nowrap\">",
"     erythema/skin",
"    </span>",
"    infiltration occurred late (median time to onset: 38 months). One-half of the affected patients required permanent drug discontinuation because of these side effects.",
"   </p>",
"   <p>",
"    Rare complications of HU include fever and abnormal liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/47\">",
"     47",
"    </a>",
"    ]. HU should not be used in pregnancy, in women with childbearing potential, and in women who are breast-feeding (",
"    <a class=\"graphic graphic_table graphicRef63410 \" href=\"mobipreview.htm?39/0/39947\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying degrees of neutropenia and anemia with megaloblastic features regularly accompany the platelet-lowering effect of HU. This is not strictly a side effect of HU, as its mechanism of action is through inhibition of DNA synthesis, resulting in a megaloblastic blood picture. In fact, if the patient's red blood cell mean corpuscular volume (MCV) does not rise significantly, this means that the patient is not taking the medication as prescribed. Therefore, a rising MCV is indicative of appropriate drug action, and is not, in and of itself, a reason to modify the dose of HU. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link&amp;anchor=H6#H6\">",
"     \"Macrocytosis\", section on 'Interference with DNA synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since HU inhibits the enzyme ribonucleotide reductase, considerably downstream from the effect of vitamins B12 and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , addition of these vitamins will not reverse HU-induced macrocytosis, anemia, neutropenia, or thrombocytopenia, and is not indicated.",
"   </p>",
"   <p>",
"    The onset of action of HU is rapid, usually within three to five days of initiation of treatment. Similarly, its effect is short-lived once the medication is stopped. Accordingly, dose adjustments should not be made more frequently than once per week in order to prevent wide fluctuations in the platelet count. It is also important to counsel patients taking HU to avoid missing drug doses.",
"   </p>",
"   <p>",
"    Complete blood counts and liver function tests should be obtained frequently within the first three months of initiation of treatment to monitor for rapid changes in blood counts as a result of drug dosage modifications, as well as to monitor for HU-induced alterations in liver function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Leukemogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both polycythemia vera (PV) and ET have an inherent tendency to evolve into acute myeloid leukemia (AML) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. For both disorders, a longer disease duration and the evolution into myelofibrosis significantly increase the risk of leukemic transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/53\">",
"     53",
"    </a>",
"    ]. However, there is, to date, no randomized study directly implicating HU as being more leukemogenic than any other therapeutic strategy, either in PV or ET.",
"   </p>",
"   <p>",
"    Several nonrandomized studies have either supported or refuted a significant increase in leukemic conversion associated with the long-term use of HU. Reported incidence rates of leukemic conversion, when HU is used alone in ET, range from 0 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/48,54-57\">",
"     48,54-57",
"    </a>",
"    ]. In one series of 357 patients followed for a median of 8 years, the incidence of conversion to myelodysplastic syndrome (MDS) or AML was 4.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54\">",
"     54",
"    </a>",
"    ]. This risk was 3.5 percent in patients treated with HU alone and 14 percent in patients receiving HU in combination with 32P,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , or pipobroman. Similar results have been obtained by other investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54,57-60\">",
"     54,57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large retrospective study of 435 patients with ET, the 15-year cumulative risk of either AML (2 percent) or MMM (4 percent) was not significantly influenced by single-agent chemotherapy of any kind, including use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/6\">",
"     6",
"    </a>",
"    ]. Consistent with this observation, the risk of leukemic transformation in two randomized trials was not adversely affected by the use of hydroxyurea alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Therefore, at present there is no hard evidence to implicate hydroxyurea use in ET as being leukemogenic, while new information suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    may increase the risk of transformation into MMM (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Anagrelide'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Nevertheless, it is legitimate to be concerned about a potential risk of mutagenicity with HU, and to avoid use of this agent in situations where the benefit of HU is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/37\">",
"     37",
"    </a>",
"    ]. One study has revealed a high frequency of 17p chromosomal deletions (41 percent) in acutely transformed patients with ET treated with HU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54\">",
"     54",
"    </a>",
"    ]. The majority also had p53 mutations and a specific type of dysgranulopoiesis (17p- syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/61\">",
"     61",
"    </a>",
"    ]. However, 17p deletions also occur in other hematologic disorders, including both de novo and treatment-related cases of AML and MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The 17p deletion in this setting may represent a nonspecific late clonal event that may or may not require the presence of antecedent chemotherapy, including HU.",
"   </p>",
"   <p>",
"    Based upon current understanding of the clonal myeloid disorders, it is not unexpected that the risk of clonal evolution is higher with aggressive, treatment-requiring disease and longer follow-up. Thus, although current information does not clearly implicate HU as being leukemogenic in patients with ET, the use of 32P or alkylating agents in patients failing treatment with HU should be discouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HU is being used increasingly in non-hematologic conditions (eg, sickle cell disease and cyanotic congenital heart disease) with no reports of associated acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In a study of 64 patients with cyanotic congenital heart disease (mean age, 25.2 years, range: 8 to 47 years) receiving HU for a mean treatment duration of 5.6 years (range: 2 to 15 years), no cases of AML or any other malignancy were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anagrelide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     Anagrelide",
"    </a>",
"    is an oral imidazoquinazoline derivative which inhibits platelet aggregation via platelet anti-cyclic AMP phosphodiesterase activity, and also has a platelet lowering effect in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/66\">",
"     66",
"    </a>",
"    ]. Three groups of investigators have studied the mechanism of anagrelide-induced platelet underproduction in the various myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Their observations suggest drug interference with megakaryocyte proliferation and maturation, resulting in platelet underproduction. The platelet function inhibitory activity of anagrelide is seen only at doses higher than those used for controlling thrombocytosis and should not be a concern in patients with ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since 1985, thousands of patients with clonal thrombocytosis (eg, CML, PV, ET, and AMM) have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. In general, the drug is capable of reducing the platelet count to less than",
"    <span class=\"nowrap\">",
"     600,000/microL",
"    </span>",
"    in more than 80 percent of previously treated and untreated patients, including children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/74\">",
"     74",
"    </a>",
"    ]. The initial adult dose is 0.5 mg, taken two to four times daily. This dose is then adjusted according to the platelet count response and symptomatology. The usual oral maintenance dose is in the range of 1 to 4",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with a median maintenance dose of 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in a group of young patients with ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/75\">",
"     75",
"    </a>",
"    ]; tachyphylaxis does not develop.",
"   </p>",
"   <p>",
"    In a separate study, which included 79 patients with ET, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    resulted in a significant reduction in the platelet count, as well as a reduction in both major and minor arterial and venous thromboembolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/76\">",
"     76",
"    </a>",
"    ]. Bleeding complications were common only in those patients who were taking anagrelide along with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Thrombosis and hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two randomized studies which compared the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in previously untreated patients with ET are discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Anagrelide versus hydroxyurea'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    is mainly related to the drug's direct vasodilatory and inotropic effects observed in both humans and animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Side effects during the first three months of treatment in a group of 35 young patients (ages 17 to 48 years) with ET included headache (34 percent),",
"    <span class=\"nowrap\">",
"     palpitations/tachycardia",
"    </span>",
"    (23 percent), fluid retention (14 percent), and diarrhea (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/75\">",
"     75",
"    </a>",
"    ]. The incidence of these side effects was reduced to 6, 8, 6, and zero percent, respectively, following long-term use in the same group of patients. A reduction in hemoglobin concentration more than 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    was seen in 24 percent following long-term treatment. Side effects resulted in discontinuation of anagrelide in three of the 35 patients (9 percent).",
"   </p>",
"   <p>",
"    In a series of 577 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    for thrombocythemic states including ET, 24 percent had fluid retention and 2 percent were diagnosed with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/70\">",
"     70",
"    </a>",
"    ]. Anagrelide use in patients with ET and polycythemia vera has been associated with acquired idiopathic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/79\">",
"     79",
"    </a>",
"    ], and must be given with caution in patients with known or suspected heart disease, which may limit its utility in the older patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/80\">",
"     80",
"    </a>",
"    ]. Anagrelide therapy has also been reported as a potential cause of high output heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9978?source=see_link\">",
"     \"High-output heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other complications after a median treatment duration of 11 years included 10 episodes of thrombosis and 7 episodes of major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/75\">",
"     75",
"    </a>",
"    ]. Each of these 17 events was associated with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;400,000/microL,",
"    </span>",
"    12 of which (71 percent) were associated with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;600,000/microL.",
"    </span>",
"    These events were probably a result of incomplete control of the disease, rather than a side effect of therapy (see",
"    <a class=\"local\" href=\"#H24\">",
"     'High risk patients'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Anagrelide versus hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have compared the efficacy, safety, and tolerability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for the treatment of ET.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9963258\">",
"    <span class=\"h4\">",
"     United Kingdom Medical Research Council Primary Thrombocythemia 1 Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this trial, 809 patients with ET diagnosed according to the Polycythemia Vera Study Group (PVSG) Criteria and considered to be at high risk for vascular events were randomly assigned to receive treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (initial dose 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    orally) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    (initial dose 0.5 mg twice per day orally); both groups also received treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/45\">",
"     45",
"    </a>",
"    ]. The doses of hydroxyurea and anagrelide were adjusted to maintain the patient's platelet count at",
"    <span class=\"nowrap\">",
"     &lt;400,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Patients were classified as being at high risk for vascular events if they met one or more of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;60 years",
"     </li>",
"     <li>",
"      Current or prior platelet count",
"      <span class=\"nowrap\">",
"       &ge;1,000,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      A history of ischemia, thrombosis, or embolism",
"     </li>",
"     <li>",
"      Hemorrhagic events caused by ET",
"     </li>",
"     <li>",
"      Hypertension requiring therapy",
"     </li>",
"     <li>",
"      Diabetes mellitus requiring treatment with a hypoglycemic agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Equivalent long-term control of the platelet count was achieved in both groups. After a median follow-up of 39 months, the composite risk of arterial thrombosis, venous thrombosis, serious hemorrhage, or death from vascular causes was significantly greater in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (odds ratio 1.6, 95% CI 1.0-2.4). Anagrelide-treated patients also experienced a significantly greater increase in bone marrow reticulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/81\">",
"     81",
"    </a>",
"    ], and a higher rate of transformation into myelofibrosis at five years (7 versus 2 percent, odds ratio 2.9, 95% CI 1.2-6.9). There were no significant differences between the two treatment arms in regard to the subsequent development of myelodysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute myeloid leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9963265\">",
"    <span class=\"h4\">",
"     Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-inferiority ANAHYDRET Study involved 259 previously untreated patients with ET at high risk for thrombohemorrhagic events. Subjects were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (initial dose 1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    (initial dose 0.5 mg twice per day); only 28 percent of the patients in either treatment arm were taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    during this trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a follow-up of 730 patient-years, the investigators concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    was not inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in preventing thrombohemorrhagic complications in patients with WHO-defined ET. Infectious events, leukopenia, and anemia were significantly more common in those taking hydroxyurea, while cardiac events (eg, hypertension, palpitations, tachycardia) were significantly more common in those taking anagrelide. No comments were made concerning the long-term risk of myelofibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9963284\">",
"    <span class=\"h4\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our concerns about the ANAHYDRET study include the non-use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the majority of patients, the severity of cardiac events in those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    , and the lack of information about the long-term risk of myelofibrosis. Accordingly, we and others recommend the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and aspirin as first line therapy in high-risk ET patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alpha interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha interferon controls the thrombocytosis associated with all myeloproliferative disorders, including ET. An overview of the reported literature indicates a 75 to 88 percent hematologic response rate, associated with a 32 percent rate of reduction in spleen size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/84-89\">",
"     84-89",
"    </a>",
"    ]. Average starting doses were 3 to 5 million units SQ daily, although doses as high as 5 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day have been used. Despite significant reduction in megakaryocyte mass, clonal hematopoiesis persists and alpha interferon is not curative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pegylated interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar efficacy along with marginally less toxicity has been observed with the use of the pegylated interferons alpha-2b and alpha-2a, which provide prolonged activity compatible with once weekly dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/89,91-93\">",
"     89,91-93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=see_link&amp;anchor=H18#H18\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Pegylated interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the overall hematologic response rate was 81 percent in 39 patients with advanced ET treated with pegylated interferon alpha-2a, while overall and complete molecular response rates for the 18 subjects with the JAK2V617F mutation were 38 and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/93\">",
"     93",
"    </a>",
"    ]. The tolerability of this agent at a dose of 90",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    was considered to be excellent, although some grade 3 toxicities were noted at that dose.",
"   </p>",
"   <p>",
"    The overall benefit to patients, compared with current treatment that usually consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , is unknown. Considering the higher cost and increased toxicity associated with interferon therapy, a controlled study is needed before endorsing treatment with interferon as standard therapy in ET.",
"   </p>",
"   <p>",
"    Accordingly, because of these cost and toxicity issues, we have restricted the use of alpha interferon in ET to high-risk women of childbearing age and to those who are pregnant. Alpha interferon may also be considered for controlling thrombocytosis in patients failing treatment with HU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pipobroman",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pipobroman is an oral piperazine derivative, structurally classified as an alkylating agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/94\">",
"     94",
"    </a>",
"    ]. The drug is not available in the United States; it is used widely in Europe for the treatment of PV and ET. Initial dose is 0.8 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO; anticipated side effects include nausea, abdominal cramps, diarrhea, stomatitis, and dry skin. In studies with short-term follow-up, acute leukemia has not been associated with the use of pipobroman in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54,95\">",
"     54,95",
"    </a>",
"    ]. However, a small risk may exist with long-term therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The risk of developing AML increases significantly when pipobroman is used with other agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Low dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA) in ET had been discouraged because of a previously demonstrated association with an increased incidence of gastrointestinal hemorrhage when ASA was used in high doses (900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in combination with another platelet antiaggregant (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , 225",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in patients with polycythemia vera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, lower doses of ASA (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    have been shown to be effective in preventing recurrent vascular events among various high-risk population groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/99\">",
"     99",
"    </a>",
"    ]. Similarly, low-dose ASA may be safe and possibly effective in preventing thrombosis in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Low-dose ASA is especially effective in treating the vasomotor symptoms of ET and PV, such as acral paresthesias and erythromelalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/39,100\">",
"     39,100",
"    </a>",
"    ]. Additional retrospective studies in ET support the value of low-dose ASA, as was also shown in a controlled study in patients with polycythemia vera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Vasomotor symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in ET is not known. Whereas low-dose aspirin given once daily is known to inhibit platelet thromboxane A",
"    <sub>",
"     2",
"    </sub>",
"    (TXA",
"    <sub>",
"     2",
"    </sub>",
"    ) synthesis by approximately 97 to 99 percent in healthy subjects through the irreversible inhibition of platelet cyclooxygenase-1 (COX-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/103\">",
"     103",
"    </a>",
"    ], the same aspirin regimen is unable to fully inhibit TXA",
"    <sub>",
"     2",
"    </sub>",
"    production in approximately 80 percent of patients with ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. This may be due to increased platelet turnover in ET, with the emergence of young platelets with intact COX-1 activity in the 24 hours between aspirin doses.",
"   </p>",
"   <p>",
"    This supposition has been supported in patients with ET in that giving the same total dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in two divided doses was more effective in normalizing the functional platelet response to aspirin than when this same dose was given once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/104\">",
"     104",
"    </a>",
"    ]. Although the clinical benefit of the use of divided doses has not yet been shown, this measure should be reserved at present for those patients with clear evidence of low-dose aspirin treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/33,106\">",
"     33,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should not be used in patients with ET and acquired von Willebrand disease. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Low risk patients with high platelet counts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Radiophosphorus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a single arm study of patients with either PV or ET treated with",
"    <strong>",
"     oral",
"    </strong>",
"    radioactive phosphorus (32P), acute leukemia developed in 4.6 percent after a median follow-up of 7.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/107\">",
"     107",
"    </a>",
"    ]. A historical comparison did not suggest inferior survival or higher leukemia incidence.",
"   </p>",
"   <p>",
"    At present, we consider the use of",
"    <strong>",
"     intravenous",
"    </strong>",
"    32P only for patients whose life expectancy is estimated to be less than 10 years. The initial recommended dose of 32P is 2.3",
"    <span class=\"nowrap\">",
"     millicuries/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously (limit 5",
"    <span class=\"nowrap\">",
"     millicuries/dose).",
"    </span>",
"    Doses of 32P should not be given more frequently than every 12 weeks. Second and subsequent doses of 32P can be increased by 25 percent (maximum dose 7 millicuries), if prior platelet count control is inadequate. However, this agent is no longer available in many locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12106002\">",
"    <span class=\"h2\">",
"     Plateletpheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of platelets by pheresis techniques has been employed in patients with ET who have extreme degrees of thrombocytosis. However, neither the degree of thrombocytosis nor the presence or absence of platelet function abnormalities consistently correlates with the clinical presentation. Although prospective randomized trials of plateletpheresis have not been conducted, this technique has generally been reserved for those with acute, serious, thrombotic or hemorrhagic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Because plateletpheresis lowers the platelet count only transiently, such treatment needs to be followed by the use of a myelosuppressive agent in order to maintain a platelet count within the recommended range (ie,",
"    <span class=\"nowrap\">",
"     &lt;400,000/microL).",
"    </span>",
"   </p>",
"   <p>",
"    Patients",
"    most likely to benefit from plateletpheresis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those with severe or life-threatening organ dysfunction (eg, cerebrovascular, digital, pulmonary) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/110-113\">",
"       110-113",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Those with acute bleeding due to acquired von Willebrand disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/114,115\">",
"       114,115",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      There is less information concerning the value of perioperative plateletpheresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/116,117\">",
"       116,117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plateletpheresis has been effective in reducing the platelet count in those refusing myelosuppressive agents, but this use is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical settings in which patients with ET and high platelet counts are least likely to benefit from plateletpheresis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When used in pregnancy to reduce the incidence of first trimester spontaneous abortions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/108,118\">",
"       108,118",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      When used in those with platelet counts",
"      <span class=\"nowrap\">",
"       &gt;1,000,000/microL",
"      </span>",
"      who are asymptomatic",
"     </li>",
"     <li>",
"      There is little or no evidence that plateletpheresis is effective in patients with reactive thrombocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of ET, based on a careful pathologic and cytogenetic review, is associated with a very low risk of either leukemic transformation or occurrence of other life-threatening complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, life expectancy in ET is minimally affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/7,17\">",
"     7,17",
"    </a>",
"    ] and the indiscriminate use of potentially harmful treatment agents is not warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/2\">",
"     2",
"    </a>",
"    ]. Once the diagnosis is adequately established, the next step is to evaluate the presence or absence of risk factors for thrombohemorrhagic complications (",
"    <a class=\"graphic graphic_table graphicRef79467 \" href=\"mobipreview.htm?3/29/3547\">",
"     table 1",
"    </a>",
"    ). The treatment of patients in each risk group, as well as management during or before pregnancy, are discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Low risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young patients with ET (age &lt;60 years) with no history of thrombosis or hemorrhage and a platelet count &lt;1.5",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    were prospectively followed and evaluated for thrombohemorrhagic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/34\">",
"     34",
"    </a>",
"    ]. The incidence of thrombosis in the study patients",
"    <span class=\"nowrap\">",
"     (1.9/100",
"    </span>",
"    patient-years) was not significantly different from that of an age- and sex-matched control population (1.5",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    patient-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/34\">",
"     34",
"    </a>",
"    ]. Similarly, minor bleeding episodes occurred rarely (1.1",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    patient-years). Of practical importance was the observation by the authors that the occurrence of pregnancy or surgical intervention in the study population was not associated with significant thrombohemorrhagic risk.",
"   </p>",
"   <p>",
"    Our experience with young women with ET is similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17\">",
"     17",
"    </a>",
"    ]. In the absence of a history of thrombosis and regardless of the platelet count, the risk of recurrent thrombosis in our patients was only 1.2",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    patient-years. These data support the practice of observation without cytoreductive therapy in young, low-risk asymptomatic patients with ET, even in those with extreme thrombocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of low-dose ASA (40 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) in low risk patients is encouraged in the presence of vasomotor symptoms or general indications for ASA use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Low risk patients with high platelet counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cytoreductive therapy in those patients with ET who have platelet counts &gt;1",
"    <span class=\"nowrap\">",
"     million/microL",
"    </span>",
"    is based on the association with an increased risk of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,17,31\">",
"     8,17,31",
"    </a>",
"    ]. In addition, extreme thrombocytosis may promote the abnormal adsorption of large von Willebrand factor (VWF) multimers and result in a hemostatic defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/114\">",
"     114",
"    </a>",
"    ]. Accordingly, such patients should be screened for the presence of acquired von Willebrand disease (VWD). Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy (eg, &le;100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is acceptable if the ristocetin cofactor level is at least 30 percent; if less than 30 percent, all aspirin should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further, we have recognized an association of extreme thrombocytosis and recurrent venous, but not arterial, thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17\">",
"     17",
"    </a>",
"    ]. Despite these observations, the incidence of major bleeding episodes, in the absence of ASA abuse, remains very low, and the episodes are often not life-threatening.",
"   </p>",
"   <p>",
"    Therefore, while it is reasonable to consider cytoreductive therapy in patients with extreme thrombocytosis, it is equally acceptable to manage those patients who do not have acquired VWD with clinical observation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as long as they avoid tobacco and doses of ASA &gt;100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    This is especially true, as will be discussed below, for young women of childbearing potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     High risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent thrombosis is unacceptably high in patients with a previous history of thrombosis or age &gt;60 years. In the only randomized study that evaluated the benefit of cytoreductive therapy in high-risk patients with ET, treatment with HU was compared with observation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/44\">",
"     44",
"    </a>",
"    ]. At a median follow-up of 27 months, the incidence of recurrent thrombosis was significantly lower in the HU group (3.6 versus 24 percent). This benefit was maintained after a median follow-up of 73 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/60\">",
"     60",
"    </a>",
"    ]. Results of this randomized study are supported by numerous uncontrolled studies that have shown reduced risk of thrombosis associated with adequate control of thrombocytosis in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,14,46\">",
"     8,14,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of importance in the selection of a platelet-lowering agent, a prospective study involving over 800 patients with ET has noted a superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    in terms of prevention of both thrombosis and transformation into myelofibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In choosing a particular platelet-lowering agent, one has to consider several patient factors including age, childbearing potential, anticipated life-expectancy, the presence of other comorbid conditions, and drug cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/121\">",
"     121",
"    </a>",
"    ]. Because of its toxicity profile, we do not use interferon alpha in patients with ET unless in the setting of either treatment failure with other agents or pregnancy (see below). It is reasonable to consider the use of radioactive phosphorus in older patients with an anticipated life-expectancy of &lt;10 years. In all other settings, we use HU as first line therapy. We strive for a target platelet count of",
"    <span class=\"nowrap\">",
"     &le;400,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8,46,75\">",
"     8,46,75",
"    </a>",
"    ]. Although safe, the additional benefit of low-dose ASA (40 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) in high risk patients receiving HU is not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/44,120\">",
"     44,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is probably thrombogenic in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/20,44\">",
"     20,44",
"    </a>",
"    ] and has been reported to alter the inhibition of in vivo platelet activation by low-dose ASA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/122\">",
"     122",
"    </a>",
"    ]. This should be emphasized to patients, especially if they wish to profit from the possible benefit of low-dose ASA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/32,123\">",
"     32,123",
"    </a>",
"    ]. Obesity is the only other cardiovascular risk factor that has been associated with thrombosis in ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/20\">",
"     20",
"    </a>",
"    ]. We do not recommend cytoreductive therapy in ET based solely on the presence of smoking or obesity; these risk factors should be managed by life-style modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pregnant women or those who desire to become pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an updated review of 43 pregnancies that have occurred in 20 patients seen at our institution, 21 (49 percent) did not result in live births, primarily because of first trimester spontaneous abortions (16 cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17,118\">",
"     17,118",
"    </a>",
"    ]. This rate of pregnancy loss is more than what is expected in the general population (15 percent). We were not able to demonstrate significant correlations between preconception clinical features (eg, platelet count, thrombohemorrhagic history, spontaneous platelet aggregation) and pregnancy outcome. The outcome of pregnancy was not different between patients who received no specific therapy and those treated with ASA alone. Three pregnancies were carried to term, and resulted in deliveries of healthy babies, despite the use of 32P or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    around the time of conception.",
"   </p>",
"   <p>",
"    The only significant predictor of spontaneous abortion was a previous history of miscarriages. On the other hand, patients who managed to sustain their pregnancy through the first trimester were able to carry their pregnancies to term without any thrombohemorrhagic or obstetric complications. Complications during delivery were infrequent, even in the absence of prophylactic platelet apheresis.",
"   </p>",
"   <p>",
"    Others have reported that pregnancy in ET may be associated with premature delivery, stillbirth, intrauterine growth retardation, placental abruption, and preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. These events were rarely encountered in our patient group. Uncontrolled studies have suggested the benefit of ASA,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and interferon alpha in reducing the incidence of miscarriages or other pregnancy-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. However, such reports suffer from an event and patient selection bias that makes it difficult to appreciate their putative antiabortive effect. Therefore, at present, it cannot be concluded that specific therapy influences the outcome of pregnancy in low- or intermediate-risk patients with ET. Our current practice is to observe these patients without specific therapy.",
"   </p>",
"   <p>",
"    In high-risk women with ET who are either pregnant or desire to become pregnant, specific therapy with a platelet-lowering agent is indicated to protect the mother from recurrent thrombosis. Because antimetabolites are primarily implicated in fetal malformations associated with chemotherapy, the use of HU in the first trimester is often discouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/130\">",
"     130",
"    </a>",
"    ]. However, in a review of the literature on the use of HU in ET, AML, CML, and sickle cell disease, there were no reports of fetal malformations in nine patients exposed to HU in the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/131\">",
"     131",
"    </a>",
"    ]. Similarly, no ill effects to the fetus were observed following second and third trimester exposures.",
"   </p>",
"   <p>",
"    The theoretical risk of teratogenicity of interferon alpha is considered to be less than that of HU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/84,124,125\">",
"     84,124,125",
"    </a>",
"    ]; there are numerous reports of successful pregnancies in patients with ET who were treated with this agent. As regards teratogenicity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    may also be safer than HU, but this agent is not currently recommended for use in pregnancy.",
"   </p>",
"   <p>",
"    Based on the above information, the current trend favors the use of interferon alpha during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/4,132\">",
"     4,132",
"    </a>",
"    ]. However, we do not consider the inadvertent exposure to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    or HU as a reason to terminate pregnancy. Instead, such patients should be reassured that inadvertent exposures to either of these agents have not resulted in adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/131\">",
"     131",
"    </a>",
"    ]. The use of anagrelide or HU should not be withheld from the high-risk pregnant woman who does not tolerate interferon alpha therapy, provided well-informed signed consent is obtained.",
"   </p>",
"   <p>",
"    Based on the above observations, it cannot be concluded that specific therapy influences pregnancy outcome in ET. Thus, we currently do not use drug therapy in low-risk patients. In case of recurrent abortions, the use of low-dose ASA or alpha-interferon is reasonable, but of unproven benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/124,126,132\">",
"     124,126,132",
"    </a>",
"    ]. The use of a platelet-lowering agent may be necessary in high-risk women. Currently, both HU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    are contraindicated for use during pregnancy. On the other hand, several successful pregnancies have been reported in patients with ET receiving therapy with alpha interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/28/32202/abstract/124,128,133,134\">",
"     124,128,133,134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with ET are asymptomatic and can be observed for months or years after the diagnosis is established before requiring treatment. Treatment strategies are based primarily on the presence or absence of risk factors for thrombosis (",
"      <a class=\"graphic graphic_table graphicRef79467 \" href=\"mobipreview.htm?3/29/3547\">",
"       table 1",
"      </a>",
"      ) and (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that low-risk patients not be treated with myelosuppressive or platelet-lowering agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Low risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of platelet-lowering agents for high risk patients with ET (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our current initial regimen of choice is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      in combination with low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H24\">",
"       'High risk patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Hydroxyurea'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Low dose aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that myelosuppressive or platelet-lowering agents not be employed in low-risk or intermediate-risk women who are either pregnant or are of childbearing age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If myelosuppressive or platelet-lowering agents are indicated in a high-risk pregnant patient with ET, we suggest the use of interferon over no treatment or treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"       anagrelide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pregnant women or those who desire to become pregnant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (eg, &le;100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally) in the presence of vasomotor symptoms or general indications for aspirin use (eg, presence of cardiovascular risk factors) and in the absence of acquired von Willebrand disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with ET should be advised to discontinue smoking and control obesity and other cardiovascular risk factors, if present. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Low dose aspirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Low risk patients with high platelet counts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/1\">",
"      Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 1998; 73:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/2\">",
"      Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/3\">",
"      Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2011; 117:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/4\">",
"      Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/5\">",
"      Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/6\">",
"      Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/7\">",
"      Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/8\">",
"      Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/9\">",
"      Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/10\">",
"      Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/11\">",
"      Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/12\">",
"      Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/13\">",
"      Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120:5128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/14\">",
"      Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/15\">",
"      Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/16\">",
"      Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 2010; 116:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/17\">",
"      Tefferi A. Risk-based management in essential thrombocythemia. ASH Education Program Book. Hematology 1999; :172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/18\">",
"      Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/19\">",
"      Randi ML, Fabris F, Cella G, et al. Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors. Angiology 1998; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/20\">",
"      Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993; 83:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/21\">",
"      Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/22\">",
"      Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/23\">",
"      Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/24\">",
"      Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/25\">",
"      Passamonti F, Rumi E, Pascutto C, et al. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/26\">",
"      De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 2010; 85:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/27\">",
"      Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol 2010; 85:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/28\">",
"      Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/29\">",
"      Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007; 109:4105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/30\">",
"      Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009; 115:5740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/31\">",
"      Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/32\">",
"      van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997; 97:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/33\">",
"      Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013; 121:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/34\">",
"      Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998; 103:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/35\">",
"      Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116:3735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/36\">",
"      Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/37\">",
"      Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000; 109:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/38\">",
"      Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/39\">",
"      Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/40\">",
"      Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/41\">",
"      Lahuerta-Palacios JJ, Bornstein R, Fern&aacute;ndez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988; 61:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/42\">",
"      Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/43\">",
"      Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/44\">",
"      Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/45\">",
"      Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/46\">",
"      Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/47\">",
"      Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012; 87:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/48\">",
"      Hern&aacute;ndez-Boluda JC, Alvarez-Larr&aacute;n A, G&oacute;mez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011; 152:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/49\">",
"      Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 2012; 118:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/50\">",
"      Shibata K, Shimamoto Y, Suga K, et al. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature. Acta Haematol 1994; 91:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/51\">",
"      Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982; 77:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/52\">",
"      Landaw SA. Acute leukemia in polycythemia vera. Semin Hematol 1976; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/53\">",
"      Emilia G, Sacchi S, Temperani P, et al. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993; 9:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/54\">",
"      Sterkers Y, Preudhomme C, La&iuml; JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/55\">",
"      Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/56\">",
"      Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997; 39:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/57\">",
"      Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia. Br J Haematol 2002; 116:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/58\">",
"      Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/59\">",
"      Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994; 52:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/60\">",
"      Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/61\">",
"      La&iuml; JL, Zandecki M, Fenaux P, et al. Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Hu&euml;t anomaly and small vacuolated granulocytes. Cancer Genet Cytogenet 1990; 46:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/62\">",
"      Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999; 13:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/63\">",
"      Hawkins JM, Moorman AV, Hoffbrand AV, et al. Association of 17p loss with late-stage or refractory disease in hematologic malignancy. Cancer Genet Cytogenet 1994; 77:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/64\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/65\">",
"      Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994; 36:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/66\">",
"      Tang SS, Frojmovic MM. Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase. J Lab Clin Med 1980; 95:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/67\">",
"      Mazur EM, Rosmarin AG, Sohl PA, et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/68\">",
"      Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/69\">",
"      Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992; 77:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/70\">",
"      Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med 1992; 92:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/71\">",
"      Mazzucconi MG, De Sanctis V, Chistolini A, et al. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992; 77:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/72\">",
"      Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997; 34:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/73\">",
"      Fruchtman SM, Petitt RM, Gilbert HS. Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferative disorders (abstract). Blood 2003; 102:32a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/74\">",
"      Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr 1995; 127:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/75\">",
"      Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/76\">",
"      Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/77\">",
"      Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984; 52:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/78\">",
"      Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/79\">",
"      Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 2004; 89:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/80\">",
"      Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004; 164:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/81\">",
"      Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/82\">",
"      Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/83\">",
"      Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005; 353:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/84\">",
"      Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/85\">",
"      Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/86\">",
"      Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/87\">",
"      Saba R, Jabbour E, Giles F, et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005; 103:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/88\">",
"      Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/89\">",
"      Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/90\">",
"      Sacchi S, Gugliotta L, Papineschi F, et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 1998; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/91\">",
"      Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/92\">",
"      Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/93\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/94\">",
"      Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine. JAMA 1967; 200:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/95\">",
"      Mazzucconi MG, Francesconi M, Chistolini A, et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol 1986; 37:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/96\">",
"      De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 2003; 123:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/97\">",
"      Passamonti F, Malabarba L, Orlandi E, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002; 116:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/98\">",
"      Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/99\">",
"      Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/100\">",
"      Fr&ouml;hli P, Graf C, Rhyner K. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid]. Schweiz Med Wochenschr 1983; 113:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/101\">",
"      Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/102\">",
"      Alvarez-Larr&aacute;n A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/103\">",
"      Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/104\">",
"      Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/105\">",
"      Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/106\">",
"      Tefferi A. Overcoming \"aspirin resistance\" in MPN. Blood 2012; 119:3377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/107\">",
"      Brandt L, Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol 1995; 54:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/108\">",
"      Greist A. The role of blood component removal in essential and reactive thrombocytosis. Ther Apher 2002; 6:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/109\">",
"      Duvall D. Therapeutic cytapheresis: Too many platelets, too many white blood cells. J Clin Apher 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/110\">",
"      Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/111\">",
"      Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apher 2000; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/112\">",
"      Taft EG, Babcock RB, Scharfman WB, Tartaglia AP. Plateletpheresis in the management of thrombocytosis. Blood 1977; 50:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/113\">",
"      Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs 1993; 16 Suppl 5:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/114\">",
"      Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/115\">",
"      Fabris F, Casonato A, Grazia del Ben M, et al. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/116\">",
"      Sch&ouml;tt U. Essential thrombocythemia and coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1994; 8:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/117\">",
"      Hsiao HT, Ou SY. Successful microsurgical tissue transfer in a patient with postsplenectomy thrombocytosis treated with platelet-phoresis. J Reconstr Microsurg 1997; 13:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/118\">",
"      Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/119\">",
"      Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006; 108:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/120\">",
"      Green A, Campbell P, Buck G, et al. The Medical Research Council PT1 trial in essential thrombocythemia (abstract). Blood 2004; 104:5a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/121\">",
"      Gilbert HS. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. Oncology (Williston Park) 2001; 15:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/122\">",
"      Pernerstorfer T, Stohlawetz P, Stummvoll G, et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol 1998; 102:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/123\">",
"      van Genderen PJ, Prins FJ, Michiels JJ, Schr&ouml;r K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999; 104:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/124\">",
"      Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma 1996; 22 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/125\">",
"      Eliyahu S, Shalev E. Essential thrombocythemia during pregnancy. Obstet Gynecol Surv 1997; 52:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/126\">",
"      Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 1996; 53:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/127\">",
"      Schmidt HH, Neumeister P, Kainer F, et al. Treatment of essential thrombocythemia during pregnancy: antiabortive effect of interferon-alpha? Ann Hematol 1998; 77:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/128\">",
"      Martinelli P, Martinelli V, Agangi A, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol 2004; 191:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/129\">",
"      Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost 2010; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/130\">",
"      Ebert U, L&ouml;ffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/131\">",
"      Diav-Citrin O, Hunnisett L, Sher GD, Koren G. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Am J Hematol 1999; 60:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/132\">",
"      Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/133\">",
"      Delage R, Demers C, Cantin G, Roy J. Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Obstet Gynecol 1996; 87:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/28/32202/abstract/134\">",
"      Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 1996; 5:74.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4486 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32202=[""].join("\n");
var outline_f31_28_32202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23741552\">",
"      - International Prognostic Score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5472315\">",
"      Overall survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5472322\">",
"      Thrombotic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for thrombosis and hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472342\">",
"      - Prior thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472349\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472363\">",
"      - Cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472370\">",
"      - Leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472415\">",
"      - Thrombocytosis and platelet function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5472478\">",
"      - Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5472486\">",
"      Thrombo-hemorrhagic risk model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - High risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leukemic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4775465\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Leukemogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anagrelide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Anagrelide versus hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9963258\">",
"      United Kingdom Medical Research Council Primary Thrombocythemia 1 Study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9963265\">",
"      Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9963284\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alpha interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pegylated interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pipobroman",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Low dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Radiophosphorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12106002\">",
"      Plateletpheresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Low risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Low risk patients with high platelet counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      High risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pregnant women or those who desire to become pregnant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4486|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/0/10255\" title=\"figure 1\">",
"      Risk groups and survival ET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/29/3547\" title=\"table 1\">",
"      Risk stratification in ET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/0/39947\" title=\"table 2\">",
"      Properties of hydroxyurea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_28_32203="Clinical features of syphilis";
var content_f31_28_32203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestation of syphilis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Primary syphilis",
"       </td>",
"       <td>",
"        Painless ulcer (chancre), adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Secondary syphilis",
"       </td>",
"       <td>",
"        Rash, mucocutaneous lesions, adenopathy, hepatitis, arthritis, glomerulonephritis, condyloma lata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Latent syphilis",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"3\">",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Early latent (&lt;1 year after infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Late latent (&gt;1 year after infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Tertiary (late) syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cutaneous disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        Gummatous lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiovascular disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        Aortic aneurysm, aortic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Central nervous system disease (neurosyphilis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tabes dorsalis, Argyll-Robertson pupils, paresis, seizures, subtle psychiatric manifestations, dementia. May be asymptomatic.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32203=[""].join("\n");
var outline_f31_28_32203=null;
var title_f31_28_32204="Syndromic hereditary neurop I";
var content_f31_28_32204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with other disorders-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Friedreich ataxia",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9q13 (frataxin)",
"       </td>",
"       <td>",
"        Usual onset before age 25 years, progressive ataxia of all limbs, optic atrophy, pyramidal signs, early loss of position and vibration sense, bladder dysfunction, distal muscle atrophy, kyphoscoliosis, cardiomyopathy, diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Infantile neuroaxonal dystrophy (PLA2G6-associated neurodegeneration)",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        22q13.1 (PLA2G6)",
"       </td>",
"       <td>",
"        Usual onset at age 1 to 3 years, motor and cognitive regression, spasticity, muscle atrophy, hypotonia, cerebellar ataxia, dystonia, optic atrophy, distal sensory loss",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Tangier disease",
"       </td>",
"       <td>",
"        AC",
"       </td>",
"       <td>",
"        9q31 (ABC1)",
"       </td>",
"       <td>",
"        Orange tonsils, hepatosplenomegaly, premature coronary disease, neuropathy, absent (homozygotes) or 50 percent normal (heterozygotes) HDL cholesterol",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Abetalipoproteinemia",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        (MTP)",
"       </td>",
"       <td>",
"        Acanthocytes, fat malabsorption, retinitis pigmentosa, peripheral neuropathy, ataxia, sensory motor neuropathy, absent tendon reflexes, low serum cholesterol and VLDL, absent serum beta lipoprotein",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Classic Refsum disease",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        PHYH",
"       </td>",
"       <td>",
"        Retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, elevated CSF protein, sensorineural deafness, ichthyosis, anosmia, abnormal accumulation of phytanic acid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Infantile Refsum disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         (PEX1)",
"        </p>",
"        <p>",
"         (PEX6)",
"        </p>",
"       </td>",
"       <td>",
"        Abnormal accumulation of phytanic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (LYST)",
"       </td>",
"       <td>",
"        Recurrent infections, partial albinism, hepatosplenomegaly, increased risk of lymphoreticular malignancy, nystagmus, seizures, mental retardation, generalized weakness, spinocerebellar degeneration, and parkinsonism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; AC: autosomal codominant; A: autosomal; ABC: ATP-binding casette recorder; MTP: microsomal triglyceride transfer protein; PHYH: phytanoyl-CoA hydroxylase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32204=[""].join("\n");
var outline_f31_28_32204=null;
var title_f31_28_32205="Mixed sleep apnea";
var content_f31_28_32205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mixed sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 226px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apnea initially appears as a central apnea (without respiratory effort as evidenced by the constant esophageal pressure [Pes]). This is followed by a period of obstructive apnea (with respiratory effort as evidenced by changes in esophageal pressure).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32205=[""].join("\n");
var outline_f31_28_32205=null;
var title_f31_28_32206="Plastic deformation";
var content_f31_28_32206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plastic deformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plastic deformation (bowing deformity) of the right radius and an oblique mid-diaphyseal ulnar fracture with posterior displacement of the distal fragment (one shaft-width).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Mathison, MD and Dewesh Agrawal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32206=[""].join("\n");
var outline_f31_28_32206=null;
var title_f31_28_32207="Pathogenesis preeclampsia";
var content_f31_28_32207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Model for pathogenesis of preeclampsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_28_32207=[""].join("\n");
var outline_f31_28_32207=null;
